

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
**WO 2004/005527 A1**

- (51) International Patent Classification<sup>7</sup>: **C12P 13/04**,  
C12N 9/02, 9/10, 9/88, 1/20, 15/10, C07H 21/04
- (21) International Application Number:  
PCT/US2002/021336  
**03 Jan 05**
- (22) International Filing Date: 3 July 2002 (03.07.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (for all designated States except US): **BASF AKTIENGESELLSCHAFT** [DE/DE]; 67056 Ludwigshafen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **YOCUM, R., Rogers** [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). **PATTERSON, Thomas, A.** [US/US]; 89 Church Street, Attleboro, MA 02760 (US). **PERO, Janice, G.** [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US). **HERMANN, Theron** [US/US]; 18 Chilhowie Drive, Kinnelon, NJ 07405 (US).
- (74) Agents: **HANLEY, Elizabeth, A. et al.**; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

(57) Abstract: The present invention features improved methods for the enhanced production of pantoate and pantothenate utilizing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities. In particular, the invention features methods for enhancing production of desired products by increasing levels of a key intermediate, ketopantoate, by increasing enzymes or substrates that contribute directly or indirectly to its synthesis. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

WO 2004/005527 A1

## MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

### Related Applications

5                   This application is related to International Patent Application No. PCT/US02/00925, entitled "Microorganisms and Processes for Enhanced Production of Pantothenate", filed January 18, 2002 (pending), and to International Patent Application No. PCT/US00/25993, entitled "Methods and Microorganisms for Production of Panto-Compounds", filed September 21, 2000 (expired). The entire content of the above-  
10                   referenced applications is incorporated herein by this reference.

### Background of the Invention

                  Pantothenate, also known as pantothenic acid or vitamin B5, is a member of the B complex of vitamins and is a nutritional requirement for mammals, including  
15                   livestock and humans (e.g., from food sources, as a water soluble vitamin supplement or as a feed additive). In cells, pantothenate is used primarily for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). These coenzymes function in the metabolism of acyl moieties which form thioesters with the sulfhydryl group of the 4'-phosphopantetheine portion of these molecules. These coenzymes are essential in all  
20                   cells, participating in over 100 different intermediary reactions in cellular metabolism.

                  The conventional means of synthesizing pantothenate (in particular, the bioactive D isomer) is *via* chemical synthesis from bulk chemicals, a process which is hampered by excessive substrate cost as well as the requirement for optical resolution of racemic intermediates. Accordingly, researchers have recently looked to bacterial or  
25                   microbial systems that produce enzymes useful in pantothenate biosynthesis processes (as bacteria are themselves capable of synthesizing pantothenate). In particular, bioconversion processes have been evaluated as a means of favoring production of the preferred isomer of pantothenic acid. Moreover, methods of direct microbial synthesis have recently been examined as a means of facilitating D-pantothenate production.

30                   There is still, however, significant need for improved pantothenate production processes, in particular, for microbial processes optimized to produce higher yields of desired product.

### Summary of the Invention

35                   The present invention relates to improved processes (e.g., microbial syntheses) for the production of pantothenate. Pantothenate production processes have been described in related applications which feature, for example, microbes engineered to overexpress key enzymes of the pantothenate biosynthetic pathway and the

isoleucine-valine biosynthetic pathway (see *e.g.*, Figure 1). Strains have been engineered that are capable of producing > 50 g/l of pantothenate in standard fermentation processes (see *e.g.*, International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). In particular, increasing the expression of the *panB*, *panC*, *panD* and *panE1* genes and increasing the expression of the *ilvBNC* and *ilvD* genes results in strains that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

In order to enhance production levels of for example, pantothenate, various improvements on the above-described methods have now been developed. For example, U.S. Patent Application Serial No. 09/667,569 describes production strains having modified (*e.g.*, deleted or decreased-activity) pantothenate kinase enzymes. In such strains, the pantothenate levels are effectively increased by decreasing utilization of pantothenate for coenzymeA ("CoA") synthesis. U.S. Patent Application Serial No. 60/262,995 further describes improved pantothenate-production strains that have been engineered to minimize utilization of various pantothenate biosynthetic enzymes and/or isoleucine-valine biosynthetic enzymes and/or their respective substrates from being used to produce an alternative product identified as [R]-3-(2-hydroxy-3-methylbutyrylamino)-propionic acid ("HMBPA").

The present invention features methods to further enhance pantothenate production by modulating a biosynthetic pathway that supplies a substrate for the pantothenate biosynthetic pathway, namely the methylenetetrahydrofolate ("MTF") biosynthetic pathway. In particular, it has been discovered that increasing levels of MTF by modification of the MTF biosynthetic pathway results in enhanced levels of the key pantothenate biosynthetic pathway intermediate, ketopantoate. Enhanced ketopantoate levels, in turn, result in significantly enhanced pantothenate production levels in appropriately engineered strains. In essence, the present inventors have identified a limiting step in the production of panto-compounds (*e.g.*, pantothenate) by strains engineered to overexpress, for example, the *panB*, *panC*, *panD*, *panE1*, *ilvBNC* and *ilvD* genes, and describe herein a means for overcoming this limitation by modification of the MTF biosynthetic pathway.

At least three effective means of modifying the MTF biosynthetic pathway are described herein. In one aspect, it has been demonstrated that increasing serine levels in the culture medium of pantothenate-producing microorganisms results in enhanced panto-compound production. It has also been demonstrated that increasing the synthesis or activity of 3-phosphoglycerate dehydrogenase (the *serA* gene product), or the synthesis or activity of serine hydroxymethyl transferase (the *glyA* gene product), thereby enhancing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms, increases panto-compound production. Increased synthesis

of 3-phosphoglycerate dehydrogenase (the *serA* gene product) is achieved, for example, by overexpressing *serA* from an appropriately-engineered expression cassette. Increased synthesis of serine hydroxymethyl transferase (the *glyA* gene product) is achieved, for example, by overexpressing *glyA* from an appropriately-engineered expression cassette.

5 Alternatively, levels of serine hydroxymethyl transferase (the *glyA* gene product) are increased by altering the regulation of the *glyA* gene. For example, mutation or deletion of the gene encoding a negative regulator (*i.e.*, repressor) of *glyA* expression, the *purR* gene, effectively increases *glyA* expression. Additional methods suitable for increasing MTF levels in panto-compound producing microorganisms involve deregulating enzymes  
10 responsible for converting glycine to MTF (*e.g.*, glycine cleavage enzymes).

Accordingly, in one aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such  
15 that pantothenate production is enhanced. In another aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities, having modified isoleucine-valine (*ilv*) biosynthetic enzymes, and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such  
20 that pantothenate production is enhanced. In particular, the invention features methods for enhancing production of desired products (*e.g.*, pantoate and/or pantothenate) by increasing the levels of a key intermediate, ketopantoate, by enzymes that contribute to its synthesis. Preferred methods result in production of pantothenate at levels greater than 50, 60, 70 or more g/L after 36 hours of culturing the microorganisms, or such that  
25 at least 60, 70, 80, 90, 100, 110, 120 or more g/L pantothenate is produced after 36 hours of culturing the microorganisms. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

30 Other features and advantages of the invention will be apparent from the following detailed description and claims.

### **Brief Description of the Drawings**

*Figure 1* is a schematic representation of the pantothenate and isoleucine-valine (*ilv*) biosynthetic pathways. Pantothenate biosynthetic enzymes are depicted in  
35 bold and their corresponding genes indicated in italics. Isoleucine-valine (*ilv*) biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics.



Figure 2 is a schematic representation of the methylenetetrahydrofolate ("MTF") biosynthetic pathway in *E. coli* (and presumably in *B. subtilis*).

Figure 3 is a schematic representation of the construction of the plasmid pAN665.

Figure 4 is a schematic representation of the construction of the plasmid pAN670.

Figure 5 is a schematic representation of the plasmid pAN004.

Figure 6 is a schematic representation of the plasmid pAN396.

Figure 7 is a schematic representation of the plasmid pAN393.

Figure 8 is a schematic representation of the structure of pAN835F, a clone of the *B. subtilis purR* gene.

Figure 9 is a schematic representation of the structure of pAN838F, a plasmid designed to install a disruption of the *B. subtilis purR* gene.

Figure 10 is a schematic representation of the structure of pAN821, a plasmid designed to delete a portion of the *serA* gene, selecting for kanamycin resistance.

Figure 11 is a schematic representation of the structure of pAN824, a plasmid designed to integrate a non-amplifiable *P26 serA* cassette at the *serA* locus, selecting for *Ser*<sup>+</sup>.

Figure 12 is a schematic representation of the structure of pAN395, a medium copy plasmid designed to integrate and amplify a *P26 serA* expression cassette at the *serA* locus.

### **Detailed Description of the Invention**

The present invention is directed to improved methods for producing panto-compounds (e.g., ketopantoate, pantoate and/or pantothenate) and strains engineered for use in said improved methods. Strains capable of producing > 50 g/l of pantothenate can be constructed as taught in International Patent Application Serial No. WO 01/21772 and in U.S. Patent Application Serial No. 60/262,995. By increasing the expression of the *panB*, *panC*, *panD* and *panE1* genes and by increasing the expression of the *ilvBNC* and *ilvD* genes, one can design strains (e.g., *Bacillus* strains) that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

However, it has now been discovered that in strains engineered to express high levels of the *panB* gene product, ketopantoate hydroxymethyltransferase (e.g., PA824, described in U.S. Patent Application Serial No. 09/667,569 and PA668-24, described in U.S. Patent Application Serial No. 60/262,995), a limiting step for further increases in the production of pantothenate is still the conversion of  $\alpha$ -ketoisovalerate ( $\alpha$ -KIV) to ketopantoate. Methods to increase the synthesis of  $\alpha$ -KIV were described

previously in International Patent Application Serial No. WO 01/21772 and U.S. Patent Application Serial No. 60/262,995. Here we disclose that even further increases in pantothenate production can be achieved by engineering panto-compound producing microorganisms such that the level of MTF, or the rate of MTF synthesis is enhanced or increased.

Accordingly, the present invention features methods for improving panto-compound production that involve modulating the methylenetetrahydrofolate ("MTF") biosynthetic pathway. In particular, increasing MTF levels in panto-compound producing microbes is an effective means of enhancing ketopantoate production, and in turn results in enhanced pantoate and/or pantothenate production in appropriately-engineered recombinant microorganisms.

Ketopantoate hydroxymethylenetransferase catalyzes the production of ketopantoate from  $\alpha$ -ketoisovalerate (" $\alpha$ -KIV") and MTF (see *e.g.*, Figure 1). In particular, the enzyme catalyzes the transfer of a hydroxymethyl group from MTF to  $\alpha$ -KIV to yield ketopantoate. Both  $\alpha$ -KIV and MTF are substrates for this reaction, and their syntheses can be increased in order to improve production of ketopantoate. The pathway for MTF biosynthesis in *E. coli* (and also in *Bacillus subtilis*) is outlined in Figure 2. MTF is synthesized from tetrahydrofolate and serine in a reaction catalyzed by the *glyA* gene that encodes serine hydroxymethyl transferase. For improved MTF synthesis the cells need increased quantities of both substrates and the product of the *glyA* gene.

In one embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (*e.g.*, having one, two, three or four pantothenate biosynthetic enzymes deregulated) and (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway (*e.g.*, having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate production is enhanced. Exemplary pantothenate biosynthetic enzymes include ketopantoate hydroxymethyltransferase, ketopantoate reductase, pantothenate synthetase and aspartate- $\alpha$ -decarboxylase. Exemplary MTF biosynthetic enzymes include the *serA* gene product and the *glyA* gene product.

In another embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (*e.g.*, having one, two, three or four pantothenate biosynthetic enzymes deregulated), (ii) a deregulated isoleucine-valine (*ilv*) biosynthetic pathway (*e.g.*, having one, two or three *ilv* biosynthetic enzymes deregulated), and (iii) a deregulated MTF biosynthetic pathway (*e.g.*, having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate

production is enhanced. Exemplary *ilv* biosynthetic enzymes include acetohydroxyacid acid synthetase, acetohydroxyacid isomeroreductase, and dihydroxyacid dehydratase.

In another embodiment, the invention features processes for the production of pantothenate that involve culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, such that at least 50 g/L pantothenate is produced after 36 hours of culturing the microorganism, preferably such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism, more preferably such that at least 70 g/L pantothenate is produced after 36 hours of culturing the microorganism, and most preferably such that at least 80 g/L pantothenate, at least 90 g/L pantothenate, at least 100 g/L pantothenate, at least 110 g/L pantothenate, or at least 120 g/L pantothenate (or more) is produced after 36 hours of culturing the microorganism.

In another embodiment, the invention features processes for the production of pantothenate that involve culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, deregulated such that at least 70 g/L pantothenate is produced after 48 hours of culturing the microorganism, preferably such that at least 80 g/L pantothenate is produced after 48 hours of culturing the microorganism, and more preferably such that at least 90 g/L pantothenate is produced after 48 hours of culturing the microorganism.

In one exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *serA* gene product in a panto-compound producing strain, for example, by expressing the *serA* gene constitutively or by introducing a feedback resistant allele of *serA*. In another exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *glyA* gene product in a panto-compound producing strain, for example, by overexpressing the *glyA* gene or modulating repression of the *glyA* gene by mutating or disrupting the *purR* gene product. In other exemplary embodiments, MTF biosynthesis is modulated by increasing serine in the culture medium or deregulating glycine cleavage enzymes.

The invention further features methods as described above, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity (e.g., wherein pantothenate kinase activity is decreased). In one embodiment, CoaA is deleted and CoaX is downregulated. In another embodiment, CoaX is deleted and CoaA is downregulated. In yet another embodiment, CoaX and CoaA are downregulated. The invention further features methods as described above, wherein the microorganisms are cultured under conditions of excess serine. The invention further features methods as

described above, wherein the microorganisms have the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of  $\beta$ -alanine feed.

Products synthesized according to the processes of the invention are also featured, as are compositions that include pantothenate produced according to said processes. Recombinant microorganisms for use in the processes of the invention are also featured. In one embodiment, the invention features a recombinant microorganism for the enhanced production of pantothenate having a deregulated pantothenate biosynthetic pathway and a deregulated MTF biosynthetic pathway. In another embodiment, the invention features a recombinant microorganism for the enhanced production of pantothenate having a deregulated pantothenate biosynthetic pathway, a deregulated MTF biosynthetic pathway and a deregulated *ilv* pathway. Microorganisms can further have reduced pantothenate kinase activity. Preferred microorganisms belong to the genus *Bacillus*, for example *Bacillus subtilis*.

As described above, certain aspects of the invention feature processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that involve culturing microorganisms having at least a deregulated pantothenate biosynthetic pathway. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway involving pantothenate biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of pantothenate. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of pantothenate in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of pantothenate *in vitro*.

As used herein, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein) such that pantothenate production is enhanced (*e.g.*, as compared to pantothenate production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). The term "pantothenate" includes the free acid form of pantothenate, also referred to as "pantothenic acid" as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of pantothenate or pantothenic acid with a cation, for example, calcium, sodium, potassium, ammonium, magnesium), also referred to as a "pantothenate salt". The term "pantothenate" also includes alcohol derivatives of pantothenate. Preferred pantothenate salts are calcium pantothenate or sodium pantothenate. A preferred alcohol derivative is pantothenol. Pantothenate salts and/or alcohols of the present invention include salts and/or alcohols prepared *via* conventional methods from the free acids described herein. In another embodiment, a pantothenate salt is synthesized directly by a microorganism of the present invention. A

pantothenate salt of the present invention can likewise be converted to a free acid form of pantothenate or pantothenic acid by conventional methodology. The term "pantothenate" is also abbreviated as "pan" herein.

Preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 1 g/L or greater. More preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 2 g/L or greater. Even more preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, overexpressed) such that pantothenate production is 10 g/L, 20 g/L, 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, or greater.

The term "pantothenate biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the pantothenate biosynthetic pathway. For example, synthesis of pantoate from  $\alpha$ -ketoisovalerate ( $\alpha$ -KIV) proceeds *via* the intermediate, ketopantoate. Formation of ketopantoate is catalyzed by the pantothenate biosynthetic enzyme PanB or ketopantoate hydroxymethyltransferase (the *panB* gene product). Formation of pantoate is catalyzed by the pantothenate biosynthetic enzyme PanE1 or ketopantoate reductase (the *panE1* gene product). Synthesis of  $\beta$ -alanine from aspartate is catalyzed by the pantothenate biosynthetic enzyme PanD or aspartate- $\alpha$ -decarboxylase (the *panD* gene product). Formation of pantothenate from pantoate and  $\beta$ -alanine (*e.g.*, condensation) is catalyzed by the pantothenate biosynthetic enzyme PanC or pantothenate synthetase (the *panC* gene product). Pantothenate biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least one pantothenate biosynthetic enzyme deregulated (*e.g.*, deregulated such that pantothenate production is enhanced), said enzyme being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- $\alpha$ -decarboxylase), PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least two pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- $\alpha$ -

decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of

5 PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- $\alpha$ -decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least four pantothenate biosynthetic enzymes deregulated, for example, a microorganism having PanB (or

10 ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- $\alpha$ -decarboxylase), and PanE1 (or ketopantoate reductase) deregulated.

In another aspect, the invention features processes for the enhanced production of pantothenate that involve culturing microorganisms having a deregulated isoleucine-valine biosynthetic pathway. The term "isoleucine-valine biosynthetic

15 pathway" includes the biosynthetic pathway involving isoleucine-valine biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of conversion of pyruvate to valine or isoleucine. The term "isoleucine-valine biosynthetic pathway" includes the biosynthetic pathway leading to

20 the synthesis of valine or isoleucine in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of valine or isoleucine *in vitro*.

As used herein, a microorganism "having a deregulated isoleucine-valine (*ilv*) pathway" includes a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, overexpressed) (both terms as defined herein)

25 such that isoleucine and/or valine and/or the valine precursor,  $\alpha$ -ketoisovalerate ( $\alpha$ -KIV) production is enhanced (*e.g.*, as compared to isoleucine and/or valine and/or  $\alpha$ -KIV production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). Figure 1 includes a schematic representation of the isoleucine-valine biosynthetic pathway. Isoleucine-valine biosynthetic enzymes

30 are depicted in bold italics and their corresponding genes indicated in italics. The term "isoleucine-valine biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the isoleucine-valine biosynthetic pathway. According to Figure 1, synthesis of valine from pyruvate proceeds *via* the intermediates, acetolactate,  $\alpha,\beta$ -dihydroxyisovalerate ( $\alpha,\beta$ -DHIV) and  $\alpha$ -ketoisovalerate

35 ( $\alpha$ -KIV). Formation of acetolactate from pyruvate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid synthetase (the *ilvBN* gene products, or alternatively, the *alsS* gene product). Formation of  $\alpha,\beta$ -DHIV from acetolactate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid

isomeroreductase (the *ilvC* gene product). Synthesis of  $\alpha$ -KIV from  $\alpha,\beta$ -DHIV is catalyzed by the isoleucine-valine biosynthetic enzyme dihydroxyacid dehydratase (the *ilvD* gene product). Moreover, valine and isoleucine can be interconverted with their respective  $\alpha$ -keto compounds by branched chain amino acid transaminases. Isoleucine-valine biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (*e.g.*, deregulated such that valine and/or isoleucine and/or  $\alpha$ -KIV production is enhanced), said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, for example, said microorganism having IlvBN or AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase) deregulated.

As mentioned herein, enzymes of the pantothenate biosynthetic pathway and/or the isoleucine-valine (*ilv*) pathway have been discovered to have an alternative activity in the synthesis of [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") or the [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway. The term "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA") biosynthetic pathway" includes the alternative biosynthetic pathway involving biosynthetic enzymes and compounds (*e.g.*, substrates and the like) traditionally associated with the pantothenate biosynthetic pathway and/or isoleucine-valine (*ilv*) biosynthetic pathway utilized in the formation or synthesis of HMBPA. The term "HMBPA biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of HMBPA in microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of HMBPA *in vitro*.

The term "HMBPA biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the HMBPA biosynthetic pathway. For example, synthesis of 2-hydroxyisovaleric acid ( $\alpha$ -HIV) from  $\alpha$ -ketoisovalerate ( $\alpha$ -KIV) is catalyzed by the *panE1* or *panE2* gene product (PanE1 is

alternatively referred to herein as ketopantoate reductase) and/or is catalyzed by the *ilvC* gene product (alternatively referred to herein as acetohydroxyacid isomeroreductase). Formation of HMBPA from  $\beta$ -alanine and  $\alpha$ -HIV is catalyzed by the *panC* gene product (alternatively referred to herein as pantothenate synthetase).

5           The term "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid ("HMBPA")" includes the free acid form of HMBPA, also referred to as "[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionate" as well as any salt thereof (*e.g.*, derived by replacing the acidic hydrogen of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate with a cation, for example,  
10   calcium, sodium, potassium, ammonium, magnesium), also referred to as a "3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid salt" or "HMBPA salt". Preferred HMBPA salts are calcium HMBPA or sodium HMBPA. HMBPA salts of the present invention include salts prepared *via* conventional methods from the free acids described herein. An HMBPA salt of the present invention can likewise be converted to a free acid  
15   form of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate by conventional methodology.

          In preferred embodiments, the invention features processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that involve culturing a microorganism having a deregulated methylenetetrahydrofolate  
20   (MTF) biosynthetic pathway. The term "methylenetetrahydrofolate (MTF) biosynthetic pathway" refers to the biosynthetic pathway involving MTF biosynthetic enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of the PanB substrate, MTF. The term "methylenetetrahydrofolate (MTF)  
25   biosynthetic pathway" refers to the biosynthetic pathway leading to the synthesis of MTF *in vivo* (*e.g.*, the pathway in *E. coli*, as depicted in Figure 2) as well as the biosynthetic pathway leading to the synthesis of MTF *in vitro*. The term "methylenetetrahydrofolate (MTF) biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (*e.g.*, intermediate or product) of the  
30   methylenetetrahydrofolate (MTF) biosynthetic pathway.

          The present invention is based, at least in part, on the discovery that deregulation of certain MTF biosynthetic enzymes results in enhanced production of MTF. A MTF biosynthetic enzyme, the deregulation of which results in enhanced MTF production, is termed a "MTF biosynthesis-enhancing enzyme". Exemplary "MTF  
35   biosynthesis-enhancing enzymes" are the *serA* gene product (3-phosphoglycerate dehydrogenase) and the *glyA* gene product (serine hydroxymethyl transferase). A microorganism "having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway", is a microorganism having at least one MTF biosynthesis-enhancing enzyme



deregulated (*e.g.*, overexpressed) such that MTF production or biosynthesis is enhanced (*e.g.*, as compared to MTF production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism).

In one embodiment, the invention features a process for the enhanced  
5 production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated "methylenetetrahydrofolate (MTF) biosynthetic pathway", as defined herein. In another embodiment, the invention features a process for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated MTF  
10 biosynthesis-enhancing enzyme. In preferred embodiments, the invention features processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes culturing a microorganism having a deregulated *glyA* gene product (serine hydroxymethyl transferase) and/or a deregulated *serA* gene product (3-phosphoglycerate dehydrogenase).

15 Yet another aspect of the present invention features processes for the enhanced production of pantothenate that include culturing microorganisms under culture conditions selected to favor pantothenate production, for example, by culturing microorganisms with excess serine (a *glyA* substrate) in the medium. The term "excess serine" includes serine levels increased or higher than those routinely utilized for  
20 culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-2.5 g/L serine. Accordingly, excess serine levels can include levels of greater than 2.5 g/L serine, for example, between about 2.5 and 10 g/L serine. Excess serine levels can include levels of greater than 5 g/L serine, for example, between about 5 and  
25 10 g/L serine.

Yet another aspect of the present invention features culturing the microorganisms described herein under conditions such that pantothenate production is further increased, for example, by increasing pantothenate and/or isoleucine-valine (*ilv*) biosynthetic pathway precursors and/or intermediates as defined herein (*e.g.*, culturing  
30 microorganisms in the presence of excess  $\beta$ -alanine, valine and/or  $\alpha$ -KIV) or, alternatively, further modifying said microorganisms such that they are capable of producing significant levels of  $\beta$ -alanine in the absence of a  $\beta$ -alanine feed (*i.e.*,  $\beta$ -alanine independent microorganisms, as described in U.S. Patent Application Serial No. 09/09/667,569).

35 Yet another aspect of the invention features further regulating pantothenate kinase activity in pantothenate-producing strains such that pantothenate production is enhanced. Pantothenate kinase is a key enzyme catalyzing the formation of Coenzyme A (CoA) from pantothenate (see *e.g.*, U.S. Patent Application Serial No.

09/09/667,569). Regulation of pantothenate kinase (*e.g.*, decreasing the activity or level of pantothenate kinase) reduces the production of CoA, favoring pantothenate accumulation. In one embodiment, pantotheante kinase activity is decreased by deleting CoaA and downregulating CoaX activity (CoaA and CoaX are both capable of catalyzing the first step in CoA biosynthesis in certain microorganisms). In another embodiment, pantothenate kinase activity is decreased by deleting CoaX and downregulating CoaA. In yet another embodiment, pantotheante kinase activity is decreased by downregulating CoaA and CoaX activities.

Various aspects of the invention are described in further detail in the following subsections.

*I. Targeting Genes Encoding Various Pantothenate and/or Isoleucine-Valine(ilv) and/or Methylenetetrahydrofolate (MTF) Biosynthetic Enzymes*

In one embodiment, the present invention features modifying or increasing the level of various biosynthetic enzymes of the pantothenate and/or isoleucine-valine(ilv) and/or methylenetetrahydrofolate (MTF) biosynthetic pathways. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term “gene”, as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), the overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An “isolated gene”, as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences that encode a second or distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated

gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences).

Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene.

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a “reduced activity” or “reduced enzymatic activity” is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a “reduced activity” or “reduced enzymatic activity” can also include an activity that has been deleted or “knocked out” (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein in a crude cell extract or isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is a temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an “increased enzymatic activity” can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a “reduced enzymatic activity” is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or producing said mutant protein or

polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue can have an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding

5 microorganism expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity)

10 sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

It will also be appreciated by the skilled artisan that nucleic acid molecules, genes, protein or polypeptides for use in the instant invention can be derived

15 from any microorganisms having a MTF biosynthetic pathway, an *ilv* biosynthetic pathway or a pantothenate biosynthetic pathway. Such nucleic acid molecules, genes, protein or polypeptides can be identified by the skilled artisan using known techniques such as homology screening, sequence comparison and the like, and can be modified by the skilled artisan in such a way that expression or production of these nucleic acid

20 molecules, genes, protein or polypeptides occurs in a recombinant microorganism (*e.g.*, by using appropriate promoters, ribosomal binding sites, expression or integration vectors, modifying the sequence of the genes such that the transcription is increased (taking into account the preferable codon usage), etc., according to techniques described herein and those known in the art).

25 In one embodiment, the genes of the present invention are derived from a Gram positive microorganism organism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). The term "derived from" (*e.g.*, "derived from" a Gram positive microorganism) refers to a gene which is naturally found in the microorganism (*e.g.*, is

30 naturally found in a Gram positive microorganism). In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium* (*e.g.*, *Corynebacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism is of

35 the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*,

*Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term “derived from *Bacillus subtilis*” or “*Bacillus subtilis*-derived” includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis purR* genes, *serA* genes, *glyA* genes, *coaX* genes, *coaA* genes, *pan* genes and/or *ilv* genes.

In another embodiment, the genes of the present invention are derived from a Gram negative (excludes basic dye) microorganism. In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism of the genus *Escherichia*. In an even more preferred embodiment, the genes of the present invention are derived from *Escherichia coli*. In another embodiment, the genes of the present invention are derived from *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

## II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* pantothenate biosynthetic genes and/or isoleucine-valine (*ilv*) biosynthetic genes and/or methylenetetrahydrofolate (MTF) biosynthetic genes. The term “recombinant nucleic acid molecule” includes a nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase “operably linked to regulatory sequence(s)” means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g.,

enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

5           The term "regulatory sequence" includes nucleic acid sequences which affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences (*i.e.*, genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it  
10 appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences (*e.g.*, to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant  
15 nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory  
20 sequences and the like) can be operably linked to a particular gene of interest.

          In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-  
25 termination signals and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring  
30 Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or  
35 repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor binding sequences, for example, a PurR binding site). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative

regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (*e.g.*, a pantothenate biosynthetic enzyme, an isoleucine-valine biosynthetic enzyme and/or a methylenetetrahydrofolate (MTF) biosynthetic enzyme) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (*e.g.*, bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (*e.g.*, a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P*<sub>15</sub>, *P*<sub>26</sub> or *P*<sub>veg</sub>, having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCACCTGTCCACCAACCAAACTGTGCTCAGT  
ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT  
CCACGCTGTGTAAAAATTTTACAAAAAGGTATTGACTTTCCCTACAGGGTGT  
GTAATAATTTAATTACAGGCGGGGGCAACCCCGCCTGT (SEQ ID NO:1),  
GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT  
GTTTTGTTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGCA  
AAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAGC  
AGGACGC (SEQ ID NO:2), and  
GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC  
GTTGATATAATTTAAATTTTATTTGACAAAAATGGGCTCGTGTGTGACAATA  
AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:3). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (*e.g.*, *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and SPO2 promoters. Additional preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *cos*, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6,  $\lambda$ -PR or  $\lambda$ -PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (*e.g.*, transcription terminator sequences). The term "terminator sequences" includes regulatory sequences that serve to terminate transcription of mRNA. Terminator



sequences (or tandem transcription terminators) can further serve to stabilize mRNA (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences that allow for detection of the vector containing  
5 said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that encode antibiotic resistance sequences or that overcome auxotrophic mutations, for example, *trpC*, drug markers, fluorescent markers, and/or colorimetric markers (*e.g.*, *lacZ*/β-galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence  
10 that gets transcribed into an artificial RBS. The term “artificial ribosome binding site (RBS)” includes a site within an mRNA molecule (*e.g.*, coded within DNA) to which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-  
15 28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of interest, for example, the native *panB* RBS TAAACATGAGGAGGAGAAAACATG (SEQ ID NO:4) or the native *panD* RBS ATTCGAGAAATGGAGAGAATATAATATG (SEQ ID NO:5)). Preferably, nucleotides that differ are substituted such that they are identical to one or  
20 more nucleotides of an ideal RBS when optimally aligned for comparisons. Ideal RBSs include, but are not limited to, AGAAAGGAGGTGA (SEQ ID NO:6), TTAAGAAAGGAGGTGANNNNATG (SEQ ID NO:7), TTAGAAAGGAGGTGANNNNATG (SEQ ID NO:8), AGAAAGGAGGTGANNNNNNATG (SEQ ID NO:9), and  
25 AGAAAGGAGGTGANNNNNNATG (SEQ ID NO:10). Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panB*, for example, of *B. subtilis panB*) include CCCTCTAGAAGGAGGAGAAAACATG (SEQ ID NO:11) and  
30 CCCTCTAGAGGAGGAGAAAACATG (SEQ ID NO:12). Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panD*, for example, of *B. subtilis panD*) include TTAGAAAGGAGGATTTAAATATG (SEQ ID NO:13), TTAGAAAGGAGGTTTAAATTAATG (SEQ ID NO:14), TTAGAAAGGAGGTGATTTAAATG (SEQ ID NO:15),  
35 TTAGAAAGGAGGTGTTTAAAATG (SEQ ID NO:16), ATTCGAGAAAGGAGG TGAATATAATATG (SEQ ID NO:17), ATTCGAGAAAGGAGGTGAATAATAATG (SEQ ID NO:18), and ATTCGTAGAAAGGAGGTGAATTAATATG (SEQ ID NO:19).

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid  
5 vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for  
10 example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences function in *E. coli*. In another embodiment, replication-enhancing sequences are derived  
15 from pBR322.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are  
20 selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo* (neomycin resistance) sequences, *kan* (kanamycin resistance) sequences and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (*e.g.*, sequences designed to allow  
25 recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product  
30 desired and the like.

### III. Recombinant Microorganisms

The present invention further features microorganisms, *i.e.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as  
35 described herein. As used herein, the term "recombinant microorganism" includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic

modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium* (e.g., *Cornyebacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated pantothenate biosynthesis pathway or enzyme, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway or enzyme and/or a modified or deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" includes a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that

the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to “deregulate” a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an “operon” (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of each gene product encoded by the operon. Alteration or modification of a regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of a gene or operon, altering nucleic acid sequences adjacent to a gene or operon (or within an operon) such as a ribosome binding site, increasing the copy number of a gene or operon, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a gene or operon and/or translation of a gene product or gene products of a gene or operon, respectively, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one pantothenate biosynthetic enzyme, at least one isoleucine-valine biosynthetic enzyme, and/or at least one MTF biosynthetic enzyme is overexpressed. The term “overexpressed” or “overexpression” includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a

particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

#### IV. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid medium) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (*e.g.*, carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy meal, soy flour, soy grits, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, growth promoters and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment,

microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (e.g., oxygen) to result in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (e.g., tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (e.g., *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (e.g., maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (e.g., rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (e.g., a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (e.g., added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation

media is added continuously to a fermentor and an equal amount of used or “conditioned” media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, pantoate and/or pantothenate). A variety of such processes have been developed and are well-known in the art.

5           The phrase “culturing under conditions such that a desired compound is produced” includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the  
10   desired amount of a compound (*e.g.*, pantoate and/or pantothenate). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a time sufficient to reach a suitable concentration of pantoate and/or pantothenate or suitable ratio of pantoate and/or pantothenate:HMBPA). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment,  
15   culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 10 g/L of compound are produced in about 36 hours, at least about 10 to 20 g/L compound are produced in about 48 hours, or at least about 20 to 30 g/L compound in  
20   about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 20 g/L of compound are produced in about 36 hours, at least about 20 to 30 g/L compound are produced in about 48 hours, or at least about 30 to 50 or 60 g/L compound in about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 40 to 60 g/L of  
25   compound are produced in about 36 hours, or at least about 60 to 90 g/L compound are produced in about 48 hours. It will be appreciated by the skilled artisan that values above the upper limits of the ranges recited may be obtainable by the processes described herein, for example, in a particular fermentation run or with a particular engineered strain.

30

          Preferably, a production method of the present invention results in production of a level of pantothenate that is “enhanced as compared to an appropriate control”. The term “appropriate control”, as defined herein, includes any control recognized by the skilled artisan as being appropriate for determining enhanced,  
35   increased, or elevated levels of desired product. For example, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example,

overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway deregulated). Likewise, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a deregulated *ilv* biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example, overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway and *ilv* biosynthetic pathway deregulated). Comparison need not be performed in each process practiced according to the present invention. For example, a skilled artisan can determine appropriate controls empirically from performing a series of reactions (*e.g.*, test tube cultures, shake flask cultures, fermentations), for example, under the same or similar conditions. Having appreciated a routine production level, for example, by a particular strain, the artisan is able to recognize levels that are enhanced, increased or elevated over such levels. In other words, comparison to an appropriate control includes comparison to a predetermined values (*e.g.*, a predetermined control).

Thus, in an embodiment wherein an appropriately engineered strain produces 40 g/L pantothenate in 36 hours (prior to manipulation such that pantothenate production is enhanced), production of 50, 60, 70 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production. Likewise, in an embodiment wherein an appropriately engineered strain produces 50 g/L pantothenate in 48 hours (prior to manipulation such that pantothenate production is enhanced), production of 60, 70, 80, 90 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production.

The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, pantoate and/or pantothenate). The term “recovering” a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound



can be recovered from culture media by first removing the microorganisms from the culture. Media are then passed through or over a cation exchange resin to remove cations and then through or over an anion exchange resin to remove inorganic anions and organic acids having stronger acidities than the compound of interest. The resulting  
5 compound can subsequently be converted to a salt (*e.g.*, a calcium salt) as described herein.

Preferably, a desired compound of the present invention is "extracted", "isolated" or "purified" such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts).  
10 The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more  
15 preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation  
20 byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

25 In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or  
30 culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

In yet another embodiment, the desired compound is partially purified. The term "partially purified" includes media preparations that have had at least some processing, for example, treatment (*e.g.*, batch treatment) with a commercial resin. In  
35 preferred embodiments, the "partially purified" preparation has greater than about 30% (by dry weight) of the desired compound, preferably greater than about 40% of the desired compound, more preferably greater than about 50% of the desired compound, still more preferably greater than about 60% of the desired compound, and most

preferably greater than about 70% desired compound. "Partially purified" preparations also preferably have 80% or less (by dry weight) of the desired compound (*i.e.*, are less pure than "extracted", "isolated" or "purified" preparations, as defined herein).

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is aspartate. In another embodiment, the biosynthetic precursor or precursor is  $\beta$ -alanine. The amount of aspartate or  $\beta$ -alanine added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of pantoate and/or pantothenate). Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time. The term "excess  $\beta$ -alanine" includes  $\beta$ -alanine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L  $\beta$ -alanine. Accordingly, excess  $\beta$ -alanine levels can include levels of about 0.01-1, preferably about 1-20 g/L.

In yet another embodiment, the biosynthetic precursor is valine. In yet another embodiment, the biosynthetic precursor is  $\alpha$ -ketoisovalerate. Preferably, valine or  $\alpha$ -ketoisovalerate is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. The term "excess  $\alpha$ -KIV" includes  $\alpha$ -KIV levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L  $\alpha$ -KIV. Accordingly, excess  $\alpha$ -KIV levels can include levels of about 0.01-1, preferably about 1-20 g/L  $\alpha$ -KIV. The term "excess valine" includes valine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.5 g/L valine. Accordingly, excess valine levels can include levels of about 0.5-5 g/L, preferably about 5-20 g/L valine.

In yet another embodiment, the biosynthetic precursor is serine.

Preferably, serine is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. Excess serine (as defined herein) can also be added according to the production processes described herein, for example, for the enhanced production of pantothenate. The skilled artisan will appreciate that extreme excesses of biosynthetic precursors can result in microorganism toxicity. Biosynthetic precursors are also referred to herein as "supplemental biosynthetic substrates".

Another aspect of the present invention includes biotransformation processes which feature the recombinant microorganisms described herein. The term "biotransformation process", also referred to herein as "bioconversion processes", includes biological processes which results in the production (*e.g.*, transformation or conversion) of appropriate substrates and/or intermediate compounds into a desired product.

The microorganism(s) and/or enzymes used in the biotransformation reactions are in a form allowing them to perform their intended function (*e.g.*, producing a desired compound). The microorganisms can be whole cells, or can be only those portions of the cells necessary to obtain the desired end result. The microorganisms can be suspended (*e.g.*, in an appropriate solution such as buffered solutions or media), rinsed (*e.g.*, rinsed free of media from culturing the microorganism), acetone-dried, immobilized (*e.g.*, with polyacrylamide gel or k-carrageenan or on synthetic supports, for example, beads, matrices and the like), fixed, cross-linked or permeablized (*e.g.*, have permeablized membranes and/or walls such that compounds, for example, substrates, intermediates or products can more easily pass through said membrane or wall).

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

## EXAMPLES

### **Example I: Panto-Compound Production Strains**

In developing *Bacillus* strains for the production of pantothenate, various genetic manipulations are made to genes and enzymes involved in the pantothenate biosynthetic pathway and the isoleucine-valine (*ilv*) pathway (Figure 1) as described in U.S. Patent Application Serial No. 09/400,494 and U.S. Patent Application Serial No. 09/667,569. For example, strains having a deregulated *panBCD* operon and/or having deregulated *panE1* exhibit enhanced pantothenate production (when cultured in the presence of  $\beta$ -alanine and  $\alpha$ -ketoisovalerate ( $\alpha$ -KIV)). Strains further deregulated for *ilvBNC* and *ilvD* exhibit enhanced pantothenate production in the presence of only  $\beta$ -alanine. Moreover, it is possible to achieve  $\beta$ -alanine independence by further deregulating *panD*.

An exemplary pantothenate production strain is PA824, a tryptophan prototroph, Spec and Tet resistant, deregulated for *panBCD* at the *panBCD* locus, deregulated for *panE1* at the *panE1* locus (two genes in the *B. subtilis* genome are homologous to *E. coli panE*, *panE1* and *panE2*, the former encoding the major ketopantoate reductase involved in pantothenate production, while *panE2* does not contribute to pantothenate synthesis (U.S. Patent Application Serial No. 09/400,494), deregulated for *ilvD* at the *ilvD* locus, overexpressing an *ilvBNC* cassette at the *amyE* locus, and overexpressing *panD* at the *bpr* locus. PA824 routinely yields approximately 40-50 g/L pantothenate, when cultured for 48 hours in 14 L fermentor vessels according to standard fermentation procedures (see *e.g.*, provisional Patent Application Serial No. 60/263,053 or provisional Patent Application Serial No. 60/262,995, incorporated by reference herein). Briefly, batch media (4.5 L) containing trace elements is inoculated with shake flask cultures of PA824. The fermentations are controlled for temperature (*e.g.*, 43°C), dissolved O<sub>2</sub>, and pH, and are run as a glucose limited fed batch process. After the initial batched glucose is consumed, glucose concentrations are maintained between about 0 and 1 g/L by continuous feeding of fresh FEED media. pH is set at 7.2, monitored, and maintained by feeding either a NH<sub>3</sub>- or a H<sub>3</sub>PO<sub>4</sub>-solution. The dissolved oxygen concentration [pO<sub>2</sub>] is maintained at about 10-30% by regulation of the agitation and aeration rate. Foaming is controlled by addition of an appropriate antifoam agent. The pantothenate titer in the fermentation broth is determined (by HPLC analysis) after removal of the cells by centrifugation.

A second exemplary strain is PA668. PA668 is a derivative of PA824 that contains extra copies of *P*<sub>26</sub> *panB* amplified at the *vpr* and/or *panB* locus. PA668 was constructed using a *panB* expression vector (pAN636) which allows for selection of multiple copies using chloramphenicol. Briefly, a pAN636 *NotI* restriction fragment

(excluding vector sequences) was ligated and then used to transform PA824 with selection on plates containing 5 µg/ml chloramphenicol. Transformants resistant to 30 µg/ml chloramphenicol were isolated and screened for pantothenate production in 48 hour test tube cultures. The isolates produce about 10 percent more pantothenate than PA824. In 10-L fermentations, a first strain, PA668-2A, produces pantothenate in amounts comparable to PA824 cultured under similar conditions (e.g., ~45-50 g/L at 36 hours). After 36 hours, when pantothenate production routinely begins to slow with PA824, PA668-2A continues to produce significant levels of pantothenate (e.g., ~60-65 g/l pantothenate at 48 hours). A second strain, PA668-24, produces pantothenate at an even faster rate, reaching 60-70 g/L after 48 hours.

A third production strain, PA721B-39, was engineered to further include an amplifiable *P*<sub>26</sub> *panBpanD* cassette as follows. First, a single expression cassette was constructed that is capable of integrating both *panB* and *panD* at the *bpr* locus. Combining both genes into one expression cassette simplifies the resulting strain by eliminating an antibiotic resistance marker. The *P*<sub>26</sub> *panBpanD* expression cassette was constructed to include each of two different *panD* ribosome binding sites (the RBSs having previously been synthesized and tested in International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). The cassette further included the synthetic *panB* gene ribosome binding site (RBS1), but the design permits future alteration of the *panB* RBS by simple oligonucleotide cassette substitution. In the first step of construction, the *panB* gene was joined to the two *panD* gene cassettes as illustrated in Figure 3 for the construction of pAN665. Next, the resulting *panBpanD* cassettes were transferred to *B. subtilis* expression vector pOTP61 as illustrated in Figure 4. A summary of the essential features of each plasmid (pAN670 and pAN674) constructed is presented in Table 1.

**Table 1. Plasmids containing various *B. subtilis* *panBpanD* gene expression cassettes.**

Plasmid	<i>panD</i> RBS	Vector	Host strain
pAN665	Standard	pASK-1BA3	<i>E. coli</i>
pAN670	"	pOTP61	<i>B. subtilis</i>
pAN669	ND-C2	pASK-1BA3	<i>E. coli</i>
pAN674	"	pOTP61	<i>B. subtilis</i>

These new plasmids combine production of extra PanB and PanD from a single vector and were predicted to produce increased levels of PanB relative to the *panB* expression vector (pAN636) present in PA668. The strategy to install the *P26 panBpanD* vectors in pantothenate production strains took advantage of genetic linkage between *bpr* and *panE1*. A derivative of PA824 was first constructed that is cured of the resident *panD* expression cassette by transforming the strain with chromosomal DNA isolated from PA930 (*panE1::cat*) and selecting for resistance to chloramphenicol. The resulting transformants were screened for sensitivity to tetracycline, and two Tet-sensitive isolates named PA715 were saved. This strain is the host strain for testing the *P26 panBpanD* vectors (see below). In order to restore the *P26 panE1* cassette in PA715, each vector was first transformed into a strain (PA328) that contains *P26 panE1* but does not contain a cassette integrated at the *bpr* locus. PA328 does contain the *P26 panBCD* locus although it is not engineered for overproduction of  $\alpha$ -KIV. Transformants of PA328 resistant to tetracycline were obtained using the appropriate *NotI* restriction fragments from the two vectors and the resulting strains were named PA710 and PA714.

The next step was to transfer the cassettes into PA715 so they could be evaluated in the PA824 strain background. This was accomplished by isolating chromosomal DNA from strains PA710 and PA714 and using each of the two DNAs separately to transform PA715, with selection for resistance to tetracycline. Tetracycline-resistant transformants were screened for sensitivity to chloramphenicol; this identifies the desired transformants that have also acquired the *P26 panE1* gene from the donor DNA by linkage with the *P26 panBpanD* cassettes at the *bpr* locus. Chloramphenicol-sensitive isolates derived from transformations in which PA710 or PA714 chromosomal DNA was used as the donor were obtained. The isolates that produced the highest pantothenate titers in test tube culture assays were saved. These strains were named PA717 and PA721, respectively. Duplicate test tube cultures of the new strains, as well as PA824 and PA715, were grown in SVY + 10 g/L aspartate at 43°C for 48 hours and then assayed for pantothenate, HMBPA, and  $\beta$ -alanine. In addition, extracts from each of the strains were run on a SDS-PAGE gel. The results of the test tube culture assays are presented in Table 2.

**Table 2.** *Production of pantothenate by strains PA717 and PA721 grown in SVY plus 10 g/l aspartate.*

Strain	<i>panBD</i> cassette	[pan] (g/L)	[HMBPA] (g/L)	[ $\beta$ -ala] (g/L)
PA824	-	4.9	0.94	2.5
"		4.6	0.79	2.3
PA715	NONE	1.7	<0.1	0.5
"	"	1.7	<0.1	0.4
PA717-24	pAN670	4.8	0.34	1.3
"	"	4.9	0.40	1.3
PA721-35	pAN674	5.7	0.50	1.4
"	"	5.3	0.40	1.3
PA721-39	pAN674	4.1	0.38	2.0
"	"	4.6	0.40	2.2

5

As expected, each of the new strains produced more pantothenate and  $\beta$ -alanine than PA715. Two of the strains (PA717-24 and PA721-39) produced about as much pantothenate as PA824 while PA721-35 produced more pantothenate than PA824. All three of the new strains produced less HMBPA than PA824. The protein gel analysis showed that the three new strains produce more PanB than any of the control strains.

10

Strains PA717-24, PA721-35, and PA721-39 were also evaluated in shake flask cultures in a soy flour based medium. As shown in Table 3, these strains with the amplifiable *P*<sub>26</sub> *panBpanD* cassette produced pantothenate and HMBPA at levels similar to the levels seen with PA668-2 and PA668-24 which both contain separate amplifiable *P*<sub>26</sub> *panB* and *P*<sub>26</sub> *panD* cassettes.

15

**Table 3. Shake Flask Experiment 48 Hours**

Medium	Strain	HMBPA (g/l)	PAN (g/l)
Soy flour + Glucose	PA668-2	1.2	6.8
	PA668-24	1.6	5.2
	PA717-24	2.0	5.9
	PA721-35	2.6	7.0
	PA721-39	2.5	8.6
Soy flour + Maltose	PA668-2	0.0	9.0
	PA668-24	0.4	10.4
	PA717-24	0.7	8.6
	PA721-35	1.0	9.2
	PA721-39	0.4	9.1

Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum (1.0 ml).

Soy Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 5g/l glutamate, 1x PSTE, 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2. 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

Average of duplicate flasks.

In addition to producing pantothenate (as well as other panto-compounds depicted in Figure 1 and described herein), it has been demonstrated that certain strains engineered for producing commercial quantities of desired panto-compound also produce a by-product identified as 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (HMBPA) (also referred to herein as “ $\beta$ -alanine 2-(*R*)-hydroxyisovalerate”, “ $\beta$ -alanine 2-hydroxyisovalerate”, “ $\beta$ -alanyl- $\alpha$ -hydroxyisovalerate” and/or “pantothenate”). (The term “pantothenate” is also abbreviated as “pan” herein.)

HMBPA is the condensation product of [*R*]- $\alpha$ -hydroxyisovaleric acid ( $\alpha$ -HIV) and  $\beta$ -alanine, catalyzed by the PanC enzyme.  $\alpha$ -HIV is generated by reduction of  $\alpha$ -KIV, a reaction that is catalyzed by the  $\alpha$ -keto reductases PanE (*e.g.*, PanE1 and/or PanE2) and/or IlvC. Thus it has been proposed that there exist at least two pathways in microorganisms that compete for  $\alpha$ -KIV, the substrate for the biosynthetic enzyme PanB, namely the pantothenate biosynthetic pathway and the HMBPA biosynthetic



pathway. (A third and fourth pathway competing for  $\alpha$ -KIV are those resulting in the production of valine or leucine from  $\alpha$ -KIV, see *e.g.*, Figure 1). At least the pantothenate biosynthetic pathway and the HMBPA biosynthetic pathway further produce competitive substrates for the enzyme PanC, namely  $\alpha$ -HIV and pantoate.

- 5 Production of HMBPA can have significant effects on pantothenate production. For example, the HMBPA pathway can compete with the pantothenate pathway for precursors ( $\alpha$ -KIV and  $\beta$ -alanine) and for some of the enzymes (PanC, PanD, PanE1, and/or IlvC). In addition, because the structure of HMBPA is similar to that of pantothenate, it may have the undesirable property of negatively regulating one or more
- 10 steps in the pantothenate pathway. Based on the identification of HMBPA, U.S. Provisional Patent Application Ser. No. 60/262,995 teaches that production of pantothenate can be improved or optimized by any means which favor use of substrates ( $\alpha$ -KIV and  $\beta$ -alanine) and/or enzymes (PanC, PanD, PanE1, and/or IlvC) in pantothenate biosynthetic processes as compared to HMBPA biosynthetic processes.

15

**Example II: Increasing Pantothenate Production by Increasing Serine Availability**

- At least one method for optimizing pantothenate production involves regulating the availability of serine in the microorganism cultures. In particular, it can
- 20 be demonstrated that increasing the availability of serine leads to increased pantothenate production (*e.g.*, relative to HMBPA production), whereas decreasing the availability of serine leads to decreased pantothenate production relative to HMBPA production. This method is based on the understanding that the compound, methylenetetrahydrofolate (MTF), which is derived from serine, donates a hydroxymethyl group to  $\alpha$ -KIV during
- 25 the pantothenate biosynthetic reaction to yield ketopantoate (see *e.g.*, Figures 1 and 2). Thus, regulating serine levels is one means of effectively regulating ketopantoate levels and, in turn, regulating pantoate and/or pantothenate production in appropriately engineered microorganisms. To demonstrate this regulation, PA824 was grown in test tube cultures of SVY glucose plus 5 g/L  $\beta$ -alanine and  $\pm$  5 g/L serine for 48 hours and
- 30 43°C.

**Table 4:** *Production of pantothenate and HMBPA by PA824 with and without the addition of serine*

serine added at 5 g/L	OD <sub>600</sub>	[pan] g/L	[HMBPA] g/L
-	16.3	4.9	0.84
-	14.0	4.5	0.80
+	13.1	6.4	0.56
+	12.9	6.0	0.62

5 As demonstrated by the data presented in Table 4, addition of serine increases the level of production of pantothenate (while conversely decreasing HMBPA production).

10 **Example III. Engineering bacterial cells with increased amounts of serine hydroxymethyl transferase, the *glyA* gene product.**

As an alternative to feeding serine, another method of increasing serine levels and/or serine utilization levels (and accordingly, methylenetetrahydrofolate levels) in order to regulate pantothenate production levels is to increase synthesis or the activity of 3-phosphoglycerate dehydrogenase or of serine hydroxymethyl transferase (the *serA* and *glyA* gene products, respectively), thereby increasing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms.

Expression of the *glyA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the *B. subtilis glyA* gene cloned downstream of a strong, constitutive promoter. To construct the expression cassette the primers RY417 and RY418 depicted in Table 5 were used to amplify the *glyA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79.

**Table 5:** *Primers used in the amplification of *B. subtilis glyA* and *serA**

RY405	CCCTCTAGAGGAGGAGAAAACATGTTTCGAGTATTGGTC TCAGACAAAATG	SEQ ID NO:20
RY406	CCCGGATCCAATTATGGCAGATCAATGAGCTTCACAGAC ACAA	SEQ ID NO:21
RY417	GGATCTAGAGGAGGTGTAAACATGAAACATTTACCTGCG CAAGACGAA	SEQ ID NO:22
RY418	CGGGGATCCCCATCAACAATTACACACTTCTATTGATT CTAC	SEQ ID NO:23

RY417 contains the RBS2 synthetic ribosome binding site just downstream from an *XbaI* site. The amplified DNA was then cut with *XbaI* and *BamHI* and cloned between the *XbaI* and *BamHI* sites in vector pAN004 (Figure 5) to yield plasmid pAN396 (Figure 6; SEQ ID NO:24). The pAN004 vector contains the phage SP01 P<sub>26</sub> promoter immediately upstream of the *XbaI* cloning site to drive expression of the cloned *glyA* gene. Just downstream of the expression cassette, pAN396 contains a *cat* gene that functions in *B. subtilis*. To transform *B. subtilis*, the *NotI* DNA fragment containing the P<sub>26</sub> *glyA* cassette and *cat* gene was isolated from pAN396, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol resistant transformants were selected and named PA1007 and PA1008. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1011 and PA1014, respectively. SDS polyacrylamide gel electrophoresis of cell extracts of selected isolates of PA1011 and PA1014 confirmed that these strains contained increased amounts of the *glyA* gene product as compared to their parent strains PA721B-39 (described in Example I) and PA824 (described in International Public. No. WO 01/21772). To test the effect of increasing *glyA* expression on pantothenate production, PA1011 and PA1014 were grown in test tube cultures of SVY glucose plus 5 g/L  $\beta$ -alanine at 43°C for 48 hours. As shown by the data presented in Table 6, PA1014 produced more pantothenate (4.5 g/L) than its parent strain PA824 (3.2 g/L). Similarly, PA1011 produced on average more pantothenate (4.35 g/L) than its parent strain PA721B-39 (4.05 g/L).

**Table 6. Production of pantothenate and HMBPA by PA1011 and PA1014 compared to PA721B-39 and PA824.**

Strain	OD <sub>600</sub>	Pantothenate g/L	HMBPA g/L
PA1014 #1	14	4.5	0.27
PA1014 #2	15	4.5	0.31
PA824	16	3.1	0.31
PA824	15	3.3	0.28
PA1011 #1	17	4.5	0.24
PA1011 #2	12	4.2	0.27
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25

**Example IV. Engineering bacterial cells with increased amounts of 3-phosphoglycerate dehydrogenase, the *serA* gene product.**

The product of the *serA* gene, 3-phosphoglycerate dehydrogenase, is the first committed enzyme in the pathway to serine biosynthesis (see Figure 2). Since serine is one of the substrates for the synthesis of MTF, we engineered the overexpression of the *serA* gene to increase serine levels in the cell. In a manner similar to that described above for the *glyA* gene in Example III, expression of the *serA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the *B. subtilis serA* gene cloned downstream of a strong, constitutive promoter. To construct the expression cassette the primers RY405 and RY406 depicted in Table 5 were used to amplify the *serA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79. The amplified DNA was then cut with *XbaI* and *BamHI* and cloned between the *XbaI* and *BamHI* sites in vector pAN004 (Figure 5) to yield plasmid pAN393 (Figure 7; SEQ ID NO:25). To transform *B. subtilis*, the *NotI* DNA fragment containing the *P<sub>26</sub> serA* cassette and *cat* gene was isolated from pAN393, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol resistant transformants were selected and named PA1004 and PA1005. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1010 and PA1013, respectively. SDS polyacrylamide gel electrophoresis of cell extracts of selected isolates of PA1010 and PA1013 confirmed that these strains contained increased amounts of the *serA* gene product as compared to their parent strains PA721B-39 and PA824.

To test the effect of increasing *serA* expression on pantothenate production, PA1010 and PA1013 were grown in test tube cultures of SVY glucose plus 5 g/L  $\beta$ -alanine at 43°C for 48 hours. As shown by the data presented in Table 7, PA1010 produced on average more pantothenate (4.7 g/L) than its parent strain PA721B-39 (4.1 g/L). Similarly, PA1013 produced on average more pantothenate (4.1 g/L) than its parent strain PA824 (3.1 g/L).

**Table 7. Production of pantothenate and HMBPA by PA1010 and PA1013 compared to PA721B-39 and PA824.**

Strain	OD <sub>600</sub>	Pantothenate g/L	HMBPA g/L
PA1010 #3	16	4.8	0.23
PA1010 #5	15	4.5	0.26
PA1010 #6	22	4.7	0.24
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25
PA1013 #2	14	3.3	0.25
PA1013 #4	14	4.2	0.28
PA1013 #5	16	5.5	0.37
PA1013 #8	13	3.6	0.24
PA824	17	3.0	0.27
PA824	16	3.1	0.29

**Example V. Shake flask and fermentor experiments with strains with increased expression of *serA* and *glyA*.**

Based on performance in test tubes, two strains with an amplifiable *serA* cassette and two strains with an amplifiable *glyA* cassette were selected, one each from two parents, PA824 and PA721B-39. The four strains were grown beside the parents in shake flasks (Table 8). In Soy flour MOPS Glucose (SMG) medium, all of the 4 strains produced more pantothenate than their parent strains. In Soy flour MOPS Maltose (SMM) medium one out of the four strains appeared superior to the parent strain.

The *serA* overexpressing strain and the *glyA* overexpressing strain from each parent were run simultaneously in 10-liter Chemap bench fermentors. The *glyA* overexpressing strain derived from PA824, PA1014-3, that had given the highest pantothenate titer in SMM, also performed the best in fermentors (Table 9). Strain PA1014-3 produced 71 g/l pantothenate in 36 hours in the culture supernatant and 86 g/l pantothenate in 48 hours in the culture supernatant compared to the parent PA824 which produced 41 g/l and 46 g/l pantothenate, respectively. The *serA* strain, PA1012-4, also produced significantly more pantothenate than the PA824 control in the culture supernatant, 52 g/l and 60 g/l at 36 and 48 hours, respectively. These results clearly demonstrate the effectiveness of increasing both *glyA* and *serA*.

The *serA* overexpressing and *glyA* overexpressing derivatives of PA721B-39 were clearly improved over their parent strain as well. Both produced about 80 g/l pantothenate (82 g/l and 79 g/l, respectively) in the culture supernatants in 48 hours. The effect of the increased PanB levels in the PA721B-39 derivatives versus the PA824 derivatives manifests itself in the reduction of HMBPA. PA721B-39 and its derivatives produce less HMBPA after 48 hours than PA824 or even PA668-24. Increasing GlyA also appears to lower the flow of carbon to HMBPA.

**Table 8. Shake flask evaluation of pantothenate production strains overexpressing *serA* or *glyA*.**

Carbon source	Strain	Added cassette	HMBPA (g/l)	Pantothenate (g/l)
Glucose	PA824		3.5	4.0
	PA1012-4	<i>serA</i>	3.0	4.6
	PA1014-3	<i>glyA</i>	2.5	4.7
	PA721B-39		0.9	5.0
	PA1010-6	<i>serA</i>	1.9	9.6
	PA1011-2	<i>glyA</i>	1.7	10.0
Maltose	PA824		1.2	10.4
	PA1012-4	<i>serA</i>	0.8	9.8
	PA1014-3	<i>glyA</i>	1.1	16.1
	PA721B-39		0.6	11.6
	PA1010-6	<i>serA</i>	0.5	10.2
	PA1011-2	<i>glyA</i>	0	10.3

All data are the average of duplicate shake flasks after 48 hours.

Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 1 x PSTE, 8 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and 5g/l glutamate. Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

Carbon Source (Sterilized separately as 20 x stock): 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

**Table 9. 10 liter fermentor evaluations of pantothenate production strains overexpressing *serA* or *glyA*.**

run	Strain	Parent	Added cassette	HMBPA (g/l)		Pantothenate (g/l)	
				36 hrs	48 hrs	36 hrs	48 hrs
P285	PA824			18	25	41	46
P284	PA1012-4	PA824	<i>serA</i>	20	21	52	60
P286	PA1014-3	PA824	<i>glyA</i>	14	16	71	86
P259	PA721B-39			4	5	34	42
P287	PA1010-6	PA721B-39	<i>serA</i>	4	5	65	82
P289	PA1011-2	PA721B-39	<i>glyA</i>	2	3	56	79
P275	PA668-24	PA824		3	9	55	72

5

The medium used is PFM-222. It is the same as medium PFM-155 described in U.S. Ser. No. 60/262,995 (filed January 19, 2001) except for the following changes: (1) In the Batch Material: There is no Amberex 1003. Cargill 200/20 (soy flour) 40 g/L has been changed to Cargill 20-80 (soy grits) 50 g/L,  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  is replaced with  $\text{MgCl}_2 \cdot 7\text{H}_2\text{O}$ , 1 g/L, and SM-1000X is replaced with PSTE-1000X (PSTE-1000X =  $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ , 2.0 g/L;  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 1.5 g/L;  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ , 2.0 g/L;  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.25 g/L;  $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ , 0.75 g/L). In the Feed Material: SM-1000X is replaced with PSTE-1000X

10

Increasing pantothenate production can also be achieved by combining overexpression of *serA* and *glyA* in a single strain, and/or by introducing a mutation that leads to feedback resistant *serA* or *glyA*, or both.

15

#### **Example VI. Increasing the expression of the *glyA* gene by mutating the *purR* gene.**

As described in Examples III and V, expression of the *glyA* gene can be increased by adding one or more copies of a cassette in which the *glyA* gene is driven by a strong, constitutive promoter. An alternative method to increase *glyA* expression is to alter its regulation. Literature describing a *glyA::lacZ* fusion suggests that the *glyA* promoter is of moderate strength under normal conditions (about 400 Miller Units), but that this promoter is capable of being induced to relatively high levels (1,800 Miller units) if its negative regulator, the *purR* gene, is deleted (Saxild *et al.* (2001) *J. Bacteriol.* 183:6175-6183). Therefore, experiments were performed to determine if *glyA*

20

25

expression, and consequently pantothenate production, could be increased by deleting *purR* from a pantothenate production strain.

The *B. subtilis purR* gene was amplified from PY79 chromosomal DNA by PCR, and the resulting fragment was cloned into PvuII cleaved pGEM5-Zf(+) vector DNA to give plasmid pAN835F (SEQ ID NO:26, Figure 8). This step eliminated the PvuII sites at both ends of the insert, leaving a unique PvuII site in the middle of the *purR* open reading frame. Next, a blunt PCR DNA fragment containing the Gram positive kanamycin resistance gene from pAN363F (SEQ ID NO:27) was ligated into this unique PvuII site of pAN835F to give pAN838F (SEQ ID NO:28, Figure 9).

pAN838F was then transformed into PY79, PA668-24, and PA824, selecting for kanamycin resistance at 10 mg/l to give new sets of strains named PA1059, PA1060, and PA1061, respectively. It was shown by PCR that all new isolates contained the disrupted *purR::kan* allele that was expected from a double crossover event. Several isolates of PA1060 and PA1061 were tested for pantothenate production in test tube cultures grown in SVY glucose plus  $\beta$ -alanine (Table 9). The best isolates derived from PA668-24, PA1060-2 and PA1060-4, gave an improvement from 3.0 g/l pantothenate to 5.3 to 5.1 g/l, respectively, which is an increase of 75%. Likewise, the best isolates derived from PA824, PA1061-1 and PA1061-2 gave an increase from about 3.1 g/l to 5.4 g/l, also a 75% gain. These results suggest that the *glyA* gene is substantially induced in these new strains by disruption of the *purR* gene. Alternatively, the improvements in pantothenate production in PA1060 and PA1061 may be due to more complex pleiotropic effects. In either case, deregulation of the *purR* regulon has a positive effect on pantothenate production.

In other embodiments, the *purR* disruption can be installed in other pantothenate production strains, for example those that have an integrated *P<sub>26</sub>serA* allele or more than one copy of the *P<sub>26</sub>panBCD* operon. The *purR* gene can also be used as a site for addition of desired expression cassettes, such as *P<sub>26</sub>panB*. One can also use resistance to the guanine analogs, such as 8-azaguanine, as a selection for a *purR* mutation.



Table 10. Production of pantothenate and fantothenate by derivatives of PA824 and PA668-24 containing disrupted *purR*, in test tube cultures grown in SVY glucose plus 5 g/l  $\beta$ -alanine.

Strain	inoculum*	parent	new feature	OD <sub>600</sub>	[fan] g/l	[pan] g/l
PA668-24	cam 5, tet 7.5	PA824	-	9	b.d.	3.0
"	"	"	-	12	b.d.	3.0
PA1060-1	cam 5, tet 7.5	PA668-24	<i>purR::kan</i>	14	0.14	4.5
PA1060-2	"	"	"	12	b.d.	5.3
PA1060-3	"	"	"	12	b.d.	4.5
PA1060-4	"	"	"	16	0.11	5.1
PA824	tet 30	PA377	-	9	0.25	3.2
"	"	"	-	11	0.22	3.0
PA1061-1	tet 15	PA824	<i>purR::kan</i>	13	0.45	5.4
PA1061-3	"	"	"	14	0.39	5.4
PA1061-4	"	"	"	11	0.40	4.7

b.d. = below detection

\* Concentration of antibiotics in the petri plate from which the inoculum colony was taken.

**Example VII. Overexpression of the *serA* gene from a non-amplifiable cassette.**

This Example describes another method to increase serine production, in which a two step procedure deposits a strong, constitutive promoter ( $P_{26}$ ) in front of the chromosomal *serA* gene. Two plasmids were constructed, each containing about 700 base pairs of DNA sequence from the region immediately upstream of the native *serA* gene. The first plasmid, pAN821, also contains the 3' half of the *serA* coding region, and in between the two aforementioned sequences, a kanamycin resistance gene (SEQ ID NO:30, Figure 10). When transformed into *B. subtilis*, selecting for kanamycin resistance, pAN821 will give a disruption of the *serA* gene, leading to serine auxotrophy. This creates a genetic sequence termed the  $\Delta serA::kan$  allele.

The second plasmid, designed to introduce the  $P_{26}$  *serA* structure, was constructed by inserting the *serA* upstream sequence at the 5' end of the  $P_{26}$  promoter in pAN395. The resulting plasmid, pAN824, is shown in Figure 11 (SEQ ID NO:31). The plasmid pAN395 is similar to pAN393 described in Example IV. The open reading frame of the *serA* gene was synthesized by PCR using *B. subtilis* PY79 DNA as the template. The upstream primer contains an *Xba*I site and a moderately strong synthetic ribosome binding site, RBS2. The downstream primer contains a *Bam*HI site. This *serA* open reading frame was used to replace the *panBCD* genes in the medium copy plasmid, pAN006, to give pAN395 (SEQ ID NO:29, Figure 12). This plasmid contains the *serA* gene expressed from the  $P_{26}$  promoter and the RBS2 ribosome binding site.

The  $\Delta serA::kan$  allele from pAN821 was introduced into strain PA824 to give PA1026. As expected, PA1026 did not grow on minimal medium. In the second step, the  $P_{26}$  *serA* cassette from plasmid pAN824 was introduced into PA1026, selecting for serine prototrophy, to give strain PA1028. Several PA1028 isolates were confirmed to have the expected chromosomal structure ( $P_{26}$  *serA*) by diagnostic PCR. These isolates were then tested for pantothenate production in test tube cultures grown for 48 hours in SVY plus 5 g/l  $\beta$ -alanine (Table 11). The PA1028 isolates (derived from PA824) gave increases from 10% to 25% in pantothenate production. As shown in Table 12, in shake flask experiments, PA824 produced about 7 g/l pantothenate, whereas PA1028 produced 11 g/l.

**Example VIII. Construction of pantothenate producing strains that contain both an integrated non-amplifiable  $P_{26}$  *serA* cassette and an amplifiable  $P_{26}$  *glyA* cassette.**

5 Since a non-amplifiable  $P_{26}$  *serA* cassette integrated at *serA* led to higher pantothenate synthesis (see, e.g., Table 12), and since a chloramphenicol amplifiable  $P_{26}$  *glyA* cassette at *glyA* led to much higher pantothenate synthesis (see, e.g., PA1014-3, Table 8), it was proposed that a combination of the two might be synergistic. Strain PA1028-4, which is the derivative of PA824 that contains the non-amplifiable  $P_{26}$  *serA* cassette integrated at *serA*, was transformed to chloramphenicol resistance at 5 mg/l using chromosomal DNA from PA1014-3, to give a set of strains named PA1038, which now contain the chloramphenicol amplifiable  $P_{26}$  *glyA* cassette. PA1038 isolates were tested for pantothenate production using standard test tube cultures grown in SVY plus  $\beta$ -alanine (Table 13). As expected, PA1038 showed a dramatic increase in pantothenate production from about 4.2 g/l by PA824 to 6.6 to 7.5 g/l by the PA1038 set. Isolates PA1038-3 and PA1038-12 were further tested in shake flasks as shown in Table 12. Both produced an average of 13.6 g/l pantothenate, as compared to the 7.4 g/l pantothenate produced by PA824.

20 **Table 11. Production of pantothenate and fantothenate by derivatives of PA824 that contain a single copy of  $P_{26}$  *serA* at the *serA* locus, in 48 hour test tube cultures grown in SVY plus 5 g/l  $\beta$ -alanine.**

Strain	parent	OD <sub>600</sub>	[fan] g/l	[pan] g/l
PA824		17	0.44	4.0
PA824		15	0.45	4.0
PA1028-1	PA824	13	0.46	4.4
PA1028-2	"	18	0.49	4.9
PA1028-3	"	15	0.44	4.4
PA1028-4	"	13	0.43	4.5
PA1028-5	"	14	0.45	4.4
PA1028-6	"	11	0.43	4.8
PA1028-8	"	15	0.51	5.0

25

b.d. = below detection

Table 12. Shake flask evaluation of pantothenate production strains overexpressing *serA* and/or *glyA*.

Strain	Parent	<i>glyA</i> cassette	<i>serA</i> cassette	Pantothenate (g/l)	Pantothenate (g/l)
PA824				0.6	7.4
PA1014-3	PA824	N x P <sub>26</sub> <i>glyA</i>		0.7	12.0
PA1028-4	PA824		P <sub>26</sub> <i>serA</i> @ <i>serA</i>	0.8	11.1
PA1038-3	PA1028-4	N x P <sub>26</sub> <i>glyA</i>	P <sub>26</sub> <i>serA</i> @ <i>serA</i>	0.5	13.6
PA1038-12	PA1028-4	N x P <sub>26</sub> <i>glyA</i>	P <sub>26</sub> <i>serA</i> @ <i>serA</i>	0.6	13.6

All data are the average of duplicate shake flasks after 48 hours.

Conditions: 40 ml medium / 200 ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Inoculum: SVY base w/maltose 24 hours at 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 5 g/l glutamate and 1x PSTE.

Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

Carbon Source (Sterilized separately as 20X stock): 30 g/l maltose, 5 mM MgCl<sub>2</sub> and 0.7 mM CaCl<sub>2</sub>.

**Table 13. Pantothenate production by PA1038, a derivative of PA824 that contains a non-amplifiable P<sub>26</sub> serA cassette at serA and an amplifiable P<sub>26</sub> glyA cassette at glyA.**

5

Strain	Inoculum Medium	OD <sub>600</sub>	[Fan] g/L	[Pan] g/L
PA824	tet 15	16	0.56	4.4
PA824	"	14	0.59	4.3
PA824	tet 30	12	0.57	4.3
PA824	"	14	0.58	4.2
PA1038-3	cam 5, tet 15	16	0.47	7.2
PA1038-4	"	14	0.49	7.0
PA1038-5	"	15	0.52	7.0
PA1038-6	"	15	0.51	7.2
PA1038-9	"	14	0.56	7.2
PA1038-11	"	13	0.49	6.6
PA1038-12	"	16	0.58	7.5

Test tube cultures were grown with SVY glucose plus 5 g/l β-alanine at 43°C for 48 hours.

10

**Example IX. Increasing the production of MTF by altering the glycine cleavage pathway.**

As demonstrated with the above examples, increasing MTF production in bacteria increases the production of pantothenate in strains that have been engineered to produce more pantothenate by manipulation of the *panBCD* and/or *panE* genes. It has been demonstrated that pantothenate production can be increased by increasing the expression of the *glyA* or the *serA* gene. Stronger promoters or ribosome binding sites can be used to increase *glyA* or *serA* expression as demonstrated in Examples III through V and VII through VIII. Alternatively, the expression of the *glyA* gene can be deregulated in *Bacillus* by disrupting the *purR* repressor gene as illustrated in Example VI.

Another method to increase MTF production is to enhance the expression of enzymes of the glycine cleavage pathway. For example, enzymes encoded by the *gcvT*, *gcvPA*, *gcvPB*, *gcvH*, and *pdhD* genes catalyze the breakdown of glycine to MTF, CO<sub>2</sub>, and NH<sub>3</sub>. A strong, constitutive promoter, such as the SP01 phage P<sub>26</sub> promoter described previously, can be cloned in front of the *gcvT-gcvPA-gcvPB* operon or in front of the *gcvH* or *pdhD* gene to enhance their expression. In addition to the above

mentioned approaches, additional glycine, which is inexpensive, can be added to the medium to further enhance MTF production by any strain engineered as described herein.

5

Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

10

What is claimed:

1. A process for the enhanced production of pantothenate, comprising culturing a microorganism having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, under conditions such that pantothenate production is enhanced.
2. A process for the enhanced production of pantothenate, comprising culturing a microorganism having
  - (i) a deregulated pantothenate biosynthetic pathway, and
  - (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway,under conditions such that pantothenate production is enhanced.
3. The process of claim 2, wherein said microorganism has at least two pantothenate biosynthetic enzymes deregulated.
4. The process of claim 2, wherein said microorganism has at least three pantothenate biosynthetic enzymes deregulated.
5. The process of claim 2, wherein said microorganism has at least four pantothenate biosynthetic enzymes deregulated.
6. The process of claim 5, wherein said microorganism has a deregulated ketopantoate hydroxymethyltransferase, a deregulated ketopantoate reductase, a deregulated pantothenate synthetase and a deregulated aspartate- $\alpha$ -decarboxylase.
7. The process of any one of claims 1 to 6, wherein said microorganism further has a deregulated isoleucine-valine (*ilv*) biosynthetic pathway.
8. The process of claim 7, wherein said microorganism has at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.
9. The process of claim 7, wherein said microorganism has at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.

10. The process of claim 9, wherein said microorganism has a deregulated acetohydroxyacid synthetase, a deregulated acetohydroxyacid isomeroreductase, and a deregulated dihydroxyacid dehydratase.

5 11. The process of any one of claims 1 to 10, wherein the microorganism has at least one MTF biosynthetic enzyme deregulated.

12. The process of claim 11, wherein the microorganism has a deregulated *glyA* gene.

10 13. The process of claim 11, wherein the microorganism has a deregulated *serA* gene.

15 14. The process of claim 11, wherein the microorganism has a deregulated *glyA* gene and a deregulated *serA* gene.

15. The process of claim 12 or 14, wherein the microorganism has a mutated, deleted or disrupted *purR* gene.

20 16. A process for the enhanced production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that production of pantothenate is enhanced.

25 17. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, such that at least 50 g/L  
30 pantothenate is produced after 36 hours of culturing the microorganism.

18. The process of claim 17, comprising culturing the microorganism such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism.

35 19. The process of claim 17, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 36 hours of culturing the microorganism.



20. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that at least 60 g/L pantothenate is produced after 48 hours of culturing the microorganism.

21. The process of claim 20, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 48 hours of culturing the microorganism.

22. The process of claim 20, comprising culturing the microorganism such that at least 80 g/L pantothenate is produced after 48 hours of culturing the microorganism.

23. The process of any one of the preceding claims, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity.

24. The process of claim 23, wherein pantothenate kinase activity is decreased.

25. The process of claim 24, wherein CoaA is deleted and CoaX is downregulated.

26. The process of claim 24, wherein CoaX is deleted and CoaA is downregulated.

27. The process of claim 24, wherein CoaX and CoaA are downregulated.

28. The process of any one of the above claims, wherein said microorganism is cultured under conditions of excess serine.

29. A process for producing pantothenate comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions of excess serine, such that pantothenate is produced.

30. The process of any one of the above claims, wherein said microorganism has the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of  $\beta$ -alanine feed.

5 31. The process of any one of the above claims wherein the microorganism is a Gram positive microorganism.

32. The process of any one of the above claims wherein the microorganism belongs to the genus *Bacillus*.

10

33. The process of any one of the above claims, wherein the microorganism is *Bacillus subtilis*.

15 34. A product synthesized according to the process of any one of the above claims.

35. A composition comprising pantothenate produced according to the process of any one of the above claims.

20 36. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway.

25 37. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, and a deregulated isoleucine-valine (*ilv*) pathway.

30 38. The microorganism of claim 36 or 37, further having reduced pantothenate kinase activity.

39. The microorganism of any one of claims 36-38 which is a Gram positive microorganism.

35 40. The microorganism of any one of claims 36-38 belonging to the genus *Bacillus*.

41. The microorganism of any one of claims 36-38 which is *Bacillus subtilis*.

42. A process for producing pantothenate comprising culturing a  
5 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) at least one deregulated isoleucine-valine (*ilv*) biosynthetic enzyme-encoding gene;

10 under conditions such that at least 30 g/l pantothenate is produced after 36 hours of culturing the microorganism.

43. The process of claim 42, wherein said microorganism further has a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway and said  
15 microorganism is cultured under conditions such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

44. A process for producing pantothenate comprising culturing a  
20 recombinant microorganism having:

- (a) a deregulated *panB* gene; and
- (b) a deregulated *panD* gene;

under conditions of excess serine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

25 45. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated methylenetetrahydrofolate (MTF) biosynthetic  
30 pathway;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

46. A process for producing pantothenate comprising culturing a  
35 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated *glyA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

47. A process for producing pantothenate comprising culturing a  
5 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a mutated, deleted or disrupted *purR* gene;

10 under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

48. A process for producing pantothenate comprising culturing a  
recombinant microorganism having:

- 15 (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated *serA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

20 49. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene;
- (c) a deregulated *serA* gene;
- 25 (d) a deregulated *glyA* gene; and

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

**FIG. 1**






FIG. 3




FIG. 4






FIG. 5




FIG. 6




FIG. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11





Fig. 12





## SEQUENCE LISTING

<110> OmniGene BioProducts, Inc. et al.

<120> MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF  
PANTOTHENATE

<130> BGI-154PC

<160> 31

<170> PatentIn Ver. 2.0

<210> 1

<211> 194

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter  
sequence

<220>

<221> -35\_signal

<222> (136)..(141)

<220>

<221> -10\_signal

<222> (159)..(164)

<400> 1

gctattgacg acagctatgg ttcactgtcc accaaccaaa actgtgctca gtaccgccaa 60  
tattttctccc ttgaggggta caaagaggtg tccctagaag agatccacgc tgtgtaaaaa 120  
ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgggg 180  
gcaacccccg ctgt 194

<210> 2

<211> 163

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter  
sequence

<220>

<221> -35\_signal

<222> (113)..(118)

<220>

<221> -10\_signal

<222> (136)..(141)

<400> 2

gcctacctag cttccaagaa agatatccta acagcacaag agcggaaaga tgttttgttc 60  
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120

atctacaagg tgttggtataa taatcttaac aacagcagga cgc

163

&lt;210&gt; 3

&lt;211&gt; 127

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:promoter  
sequence

&lt;220&gt;

&lt;221&gt; -35\_signal

&lt;222&gt; (34)..(39)

&lt;220&gt;

&lt;221&gt; -10\_signal

&lt;222&gt; (58)..(63)

&lt;220&gt;

&lt;221&gt; -35\_signal

&lt;222&gt; (75)..(80)

&lt;220&gt;

&lt;221&gt; -10\_signal

&lt;222&gt; (98)..(103)

&lt;400&gt; 3

gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60  
aatttaaatt ttatttgaca aaaatgggct cgtgtgtgtac aataaatgta gtgagggtgga 120  
tgcaatg 127

&lt;210&gt; 4

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:ribosome  
binding site

&lt;400&gt; 4

taaacatgag gaggagaaaa catg

24

&lt;210&gt; 5

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:ribosome  
binding site

&lt;400&gt; 5

attcgagaaa tggagagaat ataatatg

28

&lt;210&gt; 6

<211> 13  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<400> 6  
agaaaggagg tga

13

<210> 7  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<220>  
<221> misc\_feature  
<222> 17, 18, 19, 20  
<223> n = a, t, c, or g

<400> 7  
ttaagaaagg aggtgannnn atg

23

<210> 8  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<220>  
<221> misc\_feature  
<222> 16, 17, 18, 19, 20  
<223> n = a, c, t, or g

<400> 8  
ttagaaagga ggtgannnnn atg

23

<210> 9  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<220>  
<221> misc\_feature  
<222> 14, 15, 16, 17, 18, 19, 20  
<223> n = a, c, t, or g

<400> 9  
agaaaggagg tgannnnnnn atg 23

<210> 10  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<220>  
<221> misc\_feature  
<222> 14, 15, 16, 17, 18, 19  
<223> n = a, c, t, or g

<400> 10  
agaaaggagg tgannnnnna tg 22

<210> 11  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<400> 11  
ccctctagaa ggaggagaaa acatg 25

<210> 12  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<400> 12  
ccctctagag gaggagaaaa catg 24

<210> 13  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<400> 13  
ttagaaagga ggatttaa atg 23

<210> 14  
<211> 23  
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome  
binding site

<400> 14

ttagaaagga ggtttaatta atg

23

<210> 15

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome  
binding site

<400> 15

ttagaaagga ggtgatttaa atg

23

<210> 16

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome  
binding site

<400> 16

ttagaaagga ggtgttttaa atg

23

<210> 17

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome  
binding site

<400> 17

attcgagaaa ggaggtgaat ataatatg

28

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ribosome  
binding site

<400> 18

attcgagaaa ggaggtgaat aataatg

27

<210> 19

<211> 28

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ribosome  
binding site

<400> 19  
attcgtagaa aggaggtgaa ttaatatg 28

<210> 20  
<211> 51  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:5' PCR primer  
<223> for serA gene

<400> 20  
ccctctagag gaggagaaaa catgtttcga gtattgggtct cagacaaaat g 51

<210> 21  
<211> 43  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:3' PCR primer  
<223> for serA gene

<400> 21  
cccggatcca attatggcag atcaatgagc ttcacagaca caa 43

<210> 22  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:5' PCR primer  
<223> for glyA gene

<400> 22  
ggatctagag gaggtgtaaa catgaaacat ttacctgcgc aagacgaa 48

<210> 23  
<211> 43  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:3' PCR primer  
<223> for glyA gene

<400> 23  
cggggatccc ccatcaacaa ttacacactt ctattgattc tac 43

<210> 24

&lt;211&gt; 7926

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:serA overexpression

&lt;223&gt; plasmid

&lt;400&gt; 24

```
gaattttgCG gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggccatctt gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtcocat gaataataga aagagaaaaa gcatttttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaagggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atoccaataa cctaactctc 540
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc aggttaaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaataatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt taaaaaatat ccacttttat 900
ccaattttcg tttgttgaa taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtagcaag agttttaga aacgcaaaaa 1080
ggccatcgct caggatggcc ttctgcttaa ttgatgcct ggcagtttat ggcgggcgctc 1140
ctgcccgcca cctccgggc cgttgcttcg caacgttcaa atccgctccc ggcggttttg 1200
tcctactcag gagagcgctt accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcattgggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgct ttctgattta 1440
atctgtatca ggctgaaaaat cttctctcat ccgcaaaaac aggatccaat tatggcagat 1500
caatgagctt cacagacaca atatcaggga ctttcttag ttctttcaca attttatctt 1560
ccagatgtct gtcaaaggaa agcatcatga tggcttctcc gcctttttcc ttacggccaa 1620
cctgcatagt tgcaatgtta atatcattat ctccgagaat acgtcctact cggccgatga 1680
cacctgttgt atcttgatgc tggatataca ccaagtgacc agtcggataa aaatcaatat 1740
taaattccatt gatctcgaca attcgttctc cgaaatgagg aatatacgta gccgttacag 1800
taaagggtgt gcggtctcct gtcactttta cgctgatgca gttatcgat ccagattcag 1860
aagaggaaat tttttcactg aagctaattgc cgcgttcttt tgcgacaccc ccggcattga 1920
cctcattaac agtagagtct acgcgcggtt ttaaaaagcc tgacagaagg gcttttgtaa 1980
tgaacgatgt ttcaagttta gcaattgtgc cttcatattg aatggcaaca tccgtactg 2040
gttctttcat gcactgtgat acaaggctgc caatttttcc tgcaatttga tggtaaggct 2100
taatttttagc aaattcatct tttgtcatgg caggcaggtt gatagctgac atgacaggca 2160
ggccttttgc gaactgcaga acttcttctg acacttgggc ggcgacattg agctgtgctt 2220
ctttcgttga tgctcccaag tgaggagtgg caatgactaa tggatgatca acaagtttgt 2280
tgtcaactgg cggttcgact tcgaaaacgt caagcgctgc tcccgaaca tgcccgtttt 2340
ccaaagcttc gagaagtgtt gcttcacgca taattccgcc tcgcgcacag ttaattaagc 2400
gaaocgcttt tttcgttttt gcaatcgttt ctttattcaa taagcctttt gtttcttttg 2460
ttaaaggcgt gtgaacggta atgatatccg cactttcaag cacttcttca aatgtacggc 2520
tgtttaocgc gatttttttc gctctttctt ccgttaagaa aggatcaaaa acgtgcacag 2580
tcataccgaa cgctcctoga cgctgtgcaa tttcacttcc gattcggcct aatcctacaa 2640
taccagcgt ttttccataa agctctgaac cgacataagc tgtgcgggtt cactctctgg 2700
atttcactga gatattagcc tgcggaatgt gtctcattaa agaagagatc attgcaaatg 2760
tatgtcagc tgtcgaaatg gtgttgccgt tcggagcatt gatcacgatt acccgtgtt 2820
tcgtagcctc atcaatatcg atattatcga caccgacacc ggctcttccg acaattttta 2880
aagaagtcat tttgttgaaa aggtcttctg ttacttttgt cgcgcttcgc accaaaagag 2940
catcaaaagt atgtaattca tcttctgcat ctgctacgtt tttttgaacg atttcaataa 3000
```

agtctgattc aataagtggc tgtaaaccgt cgttgctcat tttgtctgag accaatactc 3060  
gaaacatgtt ttctcctcct ctagagcgctc ctgctgttgt taagattatt ataccacacc 3120  
ttgtagataa agtcaacaac tttttgcaaa atttttcagg aatttttagca gaggttggtc 3180  
tggtatgtaga acaaaacatc tttccgctct tgtgctgtta ggatatcttt cttggaagct 3240  
aggtaggcct cgagttatgg cagttgggta aaaggaaaca aaaagaccgt tttcacacaa 3300  
aacggtcttt ttcgatttct ttttacagtc acagccactt ttgcaaaaac cggacagctt 3360  
catgccttat aactgctgtt tcggtcgaca agcttcgcca agcggccgca aaattcactg 3420  
gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttaccaact taatcgctt 3480  
gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgac cgatcgccct 3540  
tcccaacagt tgcgcagcgt gaatggcgaa tggcgctga tgcggtattt tctccttacg 3600  
catctgtgcg gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc 3660  
gcatagttaa gccagccccg acacccgcca acacccgctg actatgcttg taaaccgttt 3720  
tgtgaaaaaa tttttaaaat aaaaaagggg acctctaggg tccccaatta attagtaata 3780  
taatctatta aaggtcattc aaaaggtcat ccaccggatc agcttagtaa agccctcgct 3840  
agattttaat gcggatgttg cgattacttc gccactatt gcgataacaa gaaaaagcca 3900  
gcctttcatg atatatctcc caatttgtgt agggcttatt atgcacgctt aaaaaataa 3960  
aaagcagact tgacctgata gtttggtgt gagcaattat gtgcttagtg catctaacgc 4020  
ttgagtttaag ccgcgcgcgc aagcggcgct ggcttgaacg aattgttaga cattatttgc 4080  
cgactacctt ggtgatctcg cctttcacgt agtggacaaa ttcttccaac tgatctgcgc 4140  
gcgaggccaa gcgatcttct tcttgtccaa gatagcctg tctagcttca agtatgacgg 4200  
gctgatactg ggccggcagg cgctccattg ccagtcggc agcgacatcc ttcggcgcca 4260  
ttttgccggt tactgcgctg taccaaatgc gggacaacgt aagcactaca tttcgctcat 4320  
cgccagccca gtcggggcgc gagttccata gcgttaaggt ttcatttagc gcctcaaata 4380  
gatcctgttc aggaaccgga tcaaagagtt cctccgcgc tggacctacc aaggcaacgc 4440  
tatgttctct tgcttttgtc agcaagatag ccagatcaat gtcgatcgtg gctggctcga 4500  
agatacctgc aagaatgtca ttgcgctgcc attctccaaa ttgcagttcg cgcttagctg 4560  
gataacgcca cggaatgatg tcgtcgtgca caacaatggt gacttctaca gcgcggagaa 4620  
tctcgctctc tccaggggaa gccgaagttt ccaaaaggct gttgatcaaa gctcgccgcg 4680  
ttgtttcctc aagccttacg gtcaccgtaa ccagcaaact aatatcactg tgtggcttca 4740  
ggccgccatc cactgcggag ccgtacaaat gtacggccag caacgtcggg tcgagatggc 4800  
gctcgatgac gccaaactacc tctgatagtt gagtcgatac ttcggcgatc accgcttccc 4860  
tcatgatgtt taactttgtt ttagggcgac tgccctgctg cgtaacatcg ttgctgctcc 4920  
ataacatcaa acatcgaccc acggcgtaac gcgcttgctg cttggatgcc cgaggcatag 4980  
actgtacccc aaaaaaacag tcataacaag ccatgaaaac cgccactgcg ccgttaccac 5040  
cgctgcgttc ggtcaagggt ctggaccagt tgcgtgagcg catacgtac ttgcattaca 5100  
gcttcgaac cgaacaggct tatgtccact ggttctgctc cttcatccgt ttccacgggtg 5160  
tgcgctaccc ggcaaccttg ggcagcagcg aagtcaggc atttctgtcc tggctggcga 5220  
acgagcgcaa ggtttcggtc tccacgcac gtcaggcatt ggccggcctt ctgttcttct 5280  
acggcaagggt gctgtgcacg gatctgccct ggcttcagga gatcggaaga cctcgccgt 5340  
cgcggcgctt gccggtggtg ctgaccccgg atgaagtgt tcgcatctc ggttttctgg 5400  
aaggcgagca tcgtttgttc gccagcttc tgtatggaac gggcatgagg atcagtgagg 5460  
gtttgcaact gcgggtcaag gatctggatt tcgatcacgg cacgatcatc gtgcgggagg 5520  
gcaagggtc caaggatcgg gccttgatgt taccgagag cttggcacc agcctgcgcg 5580  
agcaggggaa ttgatccggt ggatgacct ttgaatgacc tttaatagat tatattacta 5640  
attaattggg gacctagag gtccctttt ttattttaaa aattttttca caaaacgggt 5700  
tacaagcata acgggttttg ctgccgcaa acgggtgtt ctggtgttgc tagtttgta 5760  
tcagaatcgc agatccggct tcaggtttgc cggctgaaag cgctatttct tccagaattg 5820  
ccatgatttt ttccccacgg gaggcgtcac tggctcccgt gttgtcggca gctttgattc 5880  
gataagcagc atcgctgtt tcaggctgtc tatgtgtgac tgttgagctg taacaagttg 5940  
tctcagggtg tcaatttcat gttctagttg ctttgtttta ctggtttcac ctgttctatt 6000  
aggtgttaca tgctgttcat ctgttacatt gtcgatctgt tcatggtgaa cagctttaaa 6060  
tgcacaaaa actcgtaaaa gctctgatgt atctatctt tttacaccgt tttcatctgt 6120  
gcatattggac agttttccct ttgatattca acggtgaaca gttgttctac ttttgtttgt 6180  
tagtcttgat gcttcaactga tagatacaag agccataaga acctcagatc cttccgtatt 6240  
tagccagtat gttctctagt gtggttcgtt gtttttgcgt gagccatgag aacgaaccat 6300  
tgagatcatg cttactttgc atgtcactca aaaattttgc ctcaaaactg gtgagctgaa 6360  
tttttgcagt taaagcatcg tgtagtgtt ttcttagtcc gttacgtagg taggaatctg 6420  
atgtaatggt tgttgggtatt ttgtcaccat tcatttttat ctggttggtc tcaagttcgg 6480  
ttacgagatc catttgtcta tctagttcaa cttggaaaat caacgtatca gtcgggcggc 6540



```
ctcgccttattc aaccaccaat ttcattattgc tgaagtgtt taaatcttta cttatttggtt 6600
tcaaaaacca ttggttaagc cttttaaact catggtagtt attttcaagc attaacatga 6660
acttaaatc atcaaggcta atctctatat ttgccttggt agttttcttt tgtgtagtt 6720
cttttaataa ccactcataa atcctcatag agtatttggt ttcaaaagac ttaacatgtt 6780
ccagattata ttttatgaat ttttttaact ggaaaagata aggcaatatt tcttcactaa 6840
aaaactaatc taatttttcg cttgagaact tggcatagtt tgtccactgg aaaatctcaa 6900
agcctttaac caaaggattc ctgatttcca cagttctcgt catcagctct ctggttgctt 6960
tagctaatac accataagca ttttccctac tgatgttcat catctgagcg tattggttat 7020
aagtgaacga taccgtccgt tctttccttg tagggtttcc aatcgtgggg ttgagtagtg 7080
ccacacagca taaaattagc ttgggttcat gtcctgttaa gtcatagcga ctaatcgcta 7140
gttcatttgc tttgaaaaca actaattcag acatacatct caattggtct aggtgatttt 7200
aatcactata ccaattgaga tgggctagtc aatgataatt actagtcctt ttcctttgag 7260
ttgtgggtat ctgtaaattc tgctagacct ttgctggaaa acttgtaaat tctgctagac 7320
cctctgtaaa ttccgctaga cttttgtgtg ttttttttgt ttatatctaa gtggttataa 7380
tttatagaat aaagaaagaa taaaaaaga taaaaagaat agatcccagc cctgtgtata 7440
actcactact ttagtcagtt ccgcagttat acaaaaggat gtcgcaaagc ctggttgctc 7500
ctctacaaaa cagaccttaa aaccctaaag gcttaagtag caccctcgca agctcgggca 7560
aatcgtgaa tattcctttt gtctccgacc atcaggcacc tgagtcgctg tctttttcgt 7620
gacattcagt tcgctgcgt caccgctctg ccagtgaatg ggggtaaatg gcactacagg 7680
cgcttttat ggatttatgc aaggaaacta ccataatac aagaaaagcc cgtcacgggc 7740
ttctcagggc gttttatggc gggctctgta tgtggtgcta tctgactttt tgctgttcag 7800
cagttcctgc cctctgattt tccagttcga ccacttcgga ttatcccgtg acaggtcatt 7860
cagactggct aatgcacca gtaaggcagc ggtatcatca acaggcttac ccgtcttact 7920
gtcaac 7926
```

&lt;210&gt; 25

&lt;211&gt; 7701

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:glyA overexpression

&lt;223&gt; plasmid

&lt;400&gt; 25

```
gaattttgctg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa ccagtaaat gaagtccatg gaataataga aagagaaaaa gcatttttcag 360
gtatagggtg tttgggaaac aatttccccg aaccattata tttctctaca tcagaaagggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgctgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaataatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggtt cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt ttaaaaaatat ccacttttat 900
ccaattttcg tttgttgaa taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cgttaccaag agtttgtaga aacgcataaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggccggcgctc 1140
ctgcccgcga cctccgggc cgttgcttcg caacgttcaa atccgctccc ggccgatttg 1200
tctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcatgggggc aggtggggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgct ttctgattta 1440
```

atctgtatca ggctgaaaaat cttctctcat ccgcaaaaac aggatccccc atcaacaatt 1500  
acacacttct attgattcta caaaaaaaga cattgagttt caagaacatc gtcaaaaaac 1560  
ccgcccgggca taagcccaag cgggttttag gatcttaata atctaattct ttatataaag 1620  
gaaatttatc agtcagagca gctacacgct gtcttgcttc ttcaagtttt ccttcactct 1680  
cgtggttttt caatgcaagc gcaatgatag caccgacttc ttctaagtcg tctccgtcaa 1740  
aaccgcggct gggtacagca gctgtaccaaa gacggatgcc gcttggttac aaaggttttt 1800  
caggatcata tggaaatcgcg tttttggttag acgtaatacc aatttcatca agtacatgct 1860  
ccgcaacctt accagtcagt ccgagcgaac gaaggtcaac aaggataagg tggttgctgt 1920  
ttccgcctga aacgagctgg atgcccctct tctgtaaggc ttcagccaga cgtttcgcgt 1980  
ttgaaatgac gttttgtgca tatgttttga aatcgctctg caatacttca ccgaatgaaa 2040  
cagcttttgc ggcaataacg tgcacagag ggccgccttg aattccaggg aagatcgatt 2100  
tatcaatttt cttgccaaac tcttcacggc aaaggatcat accgccgcga ggaccgcgaa 2160  
gtgttttatg tgttggtgtt gtaacgaaat cagcgtaagg aaccgggttt ggatgaaggc 2220  
ctgccgaac aagtctgctg atatgtgcca tatccaccat gaagtaagcg ccgacttcat 2280  
cagcaatttc acggaatttc ttaaagtcga ttgtacgagg atacgcactt gctcctgcta 2340  
cgataagctt cggtttatga gcgagggctt tttcacgcac gtcacgtaa tcaatatatt 2400  
gagtttcttt atctacgcg tactcaacaa agtttatatt aacaccgctg aagttgactg 2460  
ggcttccgtg tgttaaattg ccgccgtggg agaggttcat cccaagtaca gtatcgctt 2520  
gctccaaaat cgtgaagta actgccatgt ttgcttgctg ccctgaatga ggctgaacgt 2580  
ttacatgctc cgctccaaag atttccctcg ccggtgcacg ggcgatatct tcaacgacat 2640  
cgacgtgctc gcatccgcg tagtagcggt tgcccgata tcttctgctg tacttatttg 2700  
tcaaaacaga tcttgtgct tcataaacg cttcacttac aaagttctca gaagcaatca 2760  
attcgatctt agtctgttgg cgttcacgct catttttaat ggcgtaaac acttggtcgt 2820  
cttgccgagg taaatgtttc atgtttacac ctctctaga gcgtcctgct gttgtaaga 2880  
ttattatacc acaccttgta gataaagtc acaactttt gcaaatttt tcaggaattt 2940  
tagcagaggt tgttctggat gtagaacaaa acatcttcc gctcttgctg tgttaggata 3000  
tctttcttgg aagctaggta ggccctcgag ttatggcagtt tattctttta cagtcacagc 3060  
accgttttca cacaaaacg ctttcttga ctgtttcggg cgacaagctt cgcaagcgg 3120  
aaaaccggac agcttcatgc cttataaact cgttttaca cgtcgtgact gggaaaacc 3180  
ccgcaaaatt cactggcgt cgttttaca acatccccct ttccgcagct ggcgtaatag 3240  
caacttaatc gccttgagc acatccccct agcctgaatg gcgaatggcg cctgatgcg 3300  
cgcaccgatc gcccttcca acagttgctg gtgcggtatt tcacaccgca tatggtgcac 3360  
tattttctcc ttacgcatct gtgcggtatt ccccgacacc cgccaacacc cgtgactat 3420  
atctgctctg atgccgcata gtttagccag aaaaattttt aaaataaaaa aggggacctc tagggtcccc 3480  
gcttgtaaac cgttttgtga taataaact tattaagggt tcatccacc ggatcagctt 3540  
aattaattag taatataatc ttaaatgcgg tctcccaatt tgtgtaggc ttattatgca 3600  
agtaaagccc tcgctagatt ttaagccgg tctcccaatt tgtgtaggc ttattatgca 3660  
aacaagaaaa agccagcctt tcatgatata tctcccaatt tgtgtaggc ttattatgca 3720  
cgcttaaaaa taataaaagc agacttgacc tgatagtttg gctgtgagca attatgtgct 3780  
tagtgcactc aacgcttgag ttaagccgg ccgcgaagcg gcgtcggctt gaacgaattg 3840  
ttagacatta ttgcccagct accttggtga cctcgccttt cacgtagtgg acaaatctt 3900  
ccaactgatc tgcgcgcgag gccaagcgt cttcttcttg tccaagataa gcctgtctag 3960  
cttcaagtat gacgggctga tactgggccc gcaggcgctc cattgcccag tcggcagcga 4020  
catccttcgg cgcgattttg ccggttactg cgctgtacca aatgcgggac aacgtaagca 4080  
ctacatttcg ctcatcgcca gccagtcgg cgggcgagtt ccatagcgtt aaggtttcat 4140  
ttagcgcctc aaatagatcc tgttcaggaa ccggtatcaa gagttcctcc gccgctggac 4200  
ctaccaaggc aacgctatgt tctcttgctt ttgtcagcaa gatagccaga tcaatgtcga 4260  
tcgtggctgg ctgcaagata cctgcaagaa tgtcattgct ctgccattct ccaaattgca 4320  
gttcgcgctt agctggataa cgccacggaa tgatgtcgtc gtgcacaaca atggtgactt 4380  
ctacagcgcg gagaatctcg ctctctccag gggaagccga agtttccaaa aggtcgttga 4440  
tcaaagctcg ccgcttggtt tcatcaagcc ttacggtcac cgtaaccagc aaatcaatat 4500  
cactgtgtgg cttcaggccg ccacccactg cggagccgta caaatgtacg gccagcaacg 4560  
tcggttcgag atggcgctcg atgacgccaa ctacctgta tagttgagtc gatacttcgg 4620  
cgatcaccgc ttcctctatg atgttttaact ttgttttagg gcgactgcc tgcgtgctaa 4680  
catcgttgct gctccataac atcaaacatc gacccacggc gtaacgcgct tgctgcttg 4740  
atgcccgagg catagactgt accccaaaaa aacagtcata acaagccatg aaaaccgcca 4800  
ctgcgccgtt accaccgctg cgttcgggtc aggttctgga ccagttgcgt gagcgcatat 4860  
gctacttgca ttacagctta cgaacogaac aggttatgt ccactgggtt cgtgccttca 4920  
tccgtttcca cgggtgtgct caccgcgcaa ccttgggcag cagcgaagtc gaggcatttc 4980

```
tgtcctggct ggcgaacgag cgcaagggtt cggtctccac gcatcgtcag gcattggcgg 5040
ccttgctgtt cttctacggc aaggtgctgt gcacgatct gccctggctt caggagatcg 5100
gaagacctcg gccgtcgcgg cgcttgccgg tgggtgctgac cccggatgaa gtgggttcgca 5160
tcctcgggtt tctggaaggc gagcatcgtt tgctcgccca gcttctgtat ggaacgggca 5220
tgccgatcag tgagggtttg caactgcggg tcaaggatct ggatttcgat cacggcacga 5280
tcacgtgctg ggagggaag ggctccaagg atcgggcctt gatgttacct gagagcttgg 5340
caccagacct gcgcgagcag gggaattgat ccggtggatg accttttgaa tgacctttaa 5400
tagattatat tactaattaa ttggggaccc tagagggtccc cttttttatt ttaaaaaattt 5460
tttcacaaaa cggtttacaa gcataacggg ttttgctgcc cgcaaacggg ctggttctggt 5520
gttgctagtt tggtatcaga atcgcatat cggtctcagg tttgccggct gaaagcgcta 5580
tttcttcagg aattgccatg attttttccc cacgggaggc gtcactggct cccgtgttgt 5640
cggcagcttt gattcgataa gcagcatcgc ctgtttcagg ctgtctatgt gtgactgttg 5700
agctgtaaca agttgtctca ggtgttcaat ttcattgttct agttgctttg ttttactggt 5760
ttcacctgtt ctattaggtg ttacatgctg ttcattctgtt acattgtcga tctgttcatg 5820
gtgaacagct ttaaattgcac caaaaactcg taaaagctct gatgtatcta tcttttttac 5880
accgttttca tctgtgcata tggacagttt tccctttgat atctaacggt gaacagttgt 5940
tctacttttg tttgttagtc ttgatgcttc actgatagat acaagagcca taagaacctc 6000
agatccttcc gtatttagcc agtatgttct ctagtgtggg tcgttgtttt tgcgtgagcc 6060
atgagaacga accattgaga tcatgcttac tttgcagtgc actcaaaaat tttgcctcaa 6120
aactggtgag ctgaattttt gcagttaaag catcggttag tgtttttctt agtccgttac 6180
gtaggtagga atctgatgta atggttggtg gtattttgtc accattcatt tttatctggt 6240
tgttctcaag ttcggttacg agatccattt gtctatctag ttcaacttgg aaaatcaacg 6300
tatcagtcgg gcggcctcgc ttatcaacca ccaatttcat attgctgtaa gtgtttaaat 6360
ctttacttat tggtttcaaa accattgggt taagcctttt aaactcatgg tagttatatt 6420
caagcattaa catgaactta aattcatcaa ggctaatact tataatttgc catagagtat ttgttttcaa 6480
tcttttgtgt tagttctttt aataaccact cataaatcct taactggaaa agataaggca 6540
aagacttaac atgttccaga ttatatttta tgaatttttt gaacttggca tagtttgtcc 6600
atatctcttc actaaaaact aattctaatt tttcgcttga gattcctgat ttccacagtt ctcgatcatc 6660
actggaatat ctcaaacgct ttaaccaaag gattcctgat ttccacagtt ctcgatcatc 6720
gctctctggt tgcttttagc aatacaccat aagcattttc cctactgatg ttcacatctt 6780
gagcgtattg gttataagtg aacgataccg tccgttcttt ccttgtaggg ttttcaatcg 6840
tggtggttag tagtgccaca cagcataaaa ttagcttggt ttcattgctcc gtttaagtc 6900
agcgactaat cgctagtcca tttgcttttg aaacaactaa ttcagacata catctcaatt 6960
ggtctaggtg attttaatac ctataccaat tgagatgggc tagtcaatga taattactag 7020
tccttttctt ttgagttgtg ggtatctgta aattctgcta gacctttgct ggaaaacttg 7080
taaattctgc tagacctctt gtaaatccg ctagaccttt gtgtgttttt tttgtttata 7140
ttcaagtggg tataatttat agaataaaga aagaataaaa aaagataaaa agaataagatc 7200
ccagccctgt gtataactca ctactttagt cagttccgca gtattacaaa aggatgtcgc 7260
aaacgctgtt tgctcctcta caaacagac cttaaaaccc taaaggctta agtagcacc 7320
tcgcaagctc gggcaaatcg ctgaatattc cttttgtctc cgaccatcag gcacctgagt 7380
cgctgtcttt ttcgtgacat tcagttcgct gcgctcacgg ctctggcagt gaatgggggt 7440
aaatggcact acaggcgctt tttatggatt catgcaagga aactacccat aatacaagaa 7500
aagcccgta cggtcttctc agggcggttt atggcgggtc tgctatgtgg tgctatctga 7560
ctttttgctg ttcagcagtt cctgccctct gattttccag tctgaccact tcggattatc 7620
ccgtgacagg tcattcagac tggctaattg acccagtaag gcagcgggat catcaacagg 7680
cttaccgctc ttactgtcaa c
```

&lt;210&gt; 26

&lt;211&gt; 3888

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid

&lt;400&gt; 26

```
tgcgcgcta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcgggtgcggg cctcttcgct attacgccag tttgggggtg agttcatgaa gtttcgctgc 120
agcggcagat tgggtggactt aacaaattat ttgttaaccc atccgcacga gtttaataccg 180
```

ctaaccctttt	tctctgagcg	gtatgaatct	gcaaaatcat	cgatcagtg	agattttaaca	240
attattaaac	aaacccttga	acagcagggg	attgggtactt	tgcttactgt	tcccggagct	300
gccggaggcg	ttaaataatat	tccgaaaatg	aagcaggctg	aagctgaaga	gtttgtgcag	360
acacttgagc	agtcgctggc	aaatcctgag	cgtatccttc	cgggcgggta	tgtatattta	420
acggatatct	taggaaagcc	atctgtactc	tccaaggtag	ggaagctggt	tgcttccgtg	480
tttgacagagc	gcgaaattga	tgttgtcatg	accgttgcca	cgaaaggcat	ccctcttgcg	540
tacgcagctg	caagctatct	gaatgtgcct	gttgtgatcg	ttcgtaaaga	caataaggta	600
acagagggct	ccacagtcag	cattaattac	gtttcaggct	cctcaaaccg	cattcaaaca	660
atgtcacttg	cgaaaagaag	catgaaaacg	ggttcaaacg	tactcattat	tgatgacttt	720
atgaaagcag	gcggcaccat	taatggtatg	attaacctgt	tggtatgagt	taacgcaaat	780
gtggcgggaa	tcggcgctct	agttgaagcc	gaaggagtag	atgaacgtct	tggtgacgaa	840
tatatgtcac	ttcttactct	ttcaaccatc	aacatgaaag	agaagtccat	tgaaattcag	900
aatggcaatt	ttctgctgtt	ttttaagac	aatcttttaa	agaatggaga	gacagaatca	960
tgacaaaagc	agtccacaca	aaacatgccc	cagcggcaat	cgggccttat	tcacaaggga	1020
ttatcgtcaa	caatatgttt	tacagctcag	gccaaatccc	tttgactcct	tcaggcgaaa	1080
tggtgaatgg	cgatattaag	gagcagactc	atcaagtatt	cagcaattta	aaggcgggtc	1140
tggaagaagc	gggtgcttct	tttgaaacag	ttgtaaaagc	aactgtattt	atcgcgata	1200
tggaacagtt	tgcggaagta	aacgaagtgt	acggacaata	ttttgacact	cacaaccggg	1260
cgagatcttg	tggtgaagtc	gcgagactcc	cgaaggatgc	gttagtcgag	atcgaagtta	1320
ttgcactggg	gaaataataa	gaaaagtgat	tctgggagag	ccgggatcac	ttttttatct	1380
accttatgcc	cgaaatgaaa	gctttatgac	cctgcattaa	tgaatcggcc	aacgcgcggg	1440
gagaggcggt	ttgcgtattg	ggcgctcttc	cgcttctctg	ctcactgact	cgctgcgctc	1500
ggctcgttcg	ctgcggcgag	cggtatcagc	tactcaaag	gcggtaatac	ggttatccac	1560
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	1620
ccgtaaaaag	gccgcgttgc	tggcgttttt	cgataggctc	cgccccctg	acgagcatca	1680
caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataaccagg	1740
gtttccccct	ggaagctccc	tctgctgcct	tcctgttccg	accctgccgc	ttaccggata	1800
cctgtccgcc	ttctccctt	cggggaagct	ggcgctttct	catagctcac	gctgtaggta	1860
tctcagttcg	gtgtaggctg	ttcgctccaa	gctgggctgt	gtgcacgaac	cccccgttca	1920
gcccgaaccg	tgcgcttat	ccggtaacta	tcgtcttgag	tccaaccggg	taagacacga	1980
cttatcgcca	ctggcagcag	ccactggtaa	caggattagc	agagcgaggt	atgtaggcgg	2040
tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	2100
tatctgcgct	ctgctgaagc	cagttacctt	cgaaaaaaga	gttggtagct	cttgatccgg	2160
caaaacaaacc	accgctggta	gcggtggttt	ttttgtttgc	aagcagcaga	ttacgcgcga	2220
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	2280
cgaaaactca	tgtaaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	2340
ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	2400
tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcggtc	2460
atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	2520
tggtcccag	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atztatcagc	2580
aataaaccag	ccagccggaa	gggcccagcg	cagaagtgg	cctgcaactt	tatccgcctc	2640
catccagctc	attaattgtt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	2700
gcgcaacgtt	gttggcattg	ctacaggcat	cgtgggtgtc	cgctcgtcgt	ttggtagggc	2760
ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	tgatccccc	tggtgtgcaa	2820
aaaagcgggt	agtccttcg	gtcctccgat	cggtgtcaga	agtaagttgg	ccgcagtggt	2880
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	2940
cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaataccgcg	cccgcgacc	3000
gagttgctct	tgccggcggt	caatacggga	taatagtgt	tgacatagca	gaactttaaa	3060
agtgtcatc	attggaaaac	gttcttcggg	gcgaaaactc	tcaaggatct	taccgctgtt	3120
gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	3180
caccagcggt	tctgggtgag	caaaaacagg	aaggcaaaat	gccgcaaaaa	agggaataag	3240
ggcgacacgg	aaatgttgaa	tactcatact	cttctctttt	caatattatt	gaagcattta	3300
tcagggttat	tgtctcatga	gcggatacat	atttgaatgt	atthagaaaa	ataaacaaat	3360
aggggttccg	cgcacatttc	cccgaagaag	gccacctgta	tgcggtgtga	aataccgcac	3420
agatgcgtaa	ggagaaaata	ccgcatcagg	cgaaattgta	aacgttaata	ttttgttaaa	3480
attcgcgtta	aatatttgtt	aatcagctc	attttttaac	caataggccg	aaatcggcaa	3540
aatcccttat	aatcaaaag	aatagaccga	gatagggttg	agtgttggtc	cagtttgtaa	3600
caagagtcca	ctattaaaga	acgtggactc	caacgtcaaa	gggcgaaaaa	ccgtctatca	3660
gggcgatggc	ccactacgtg	aaccatcacc	caaatcaagt	tttttgcggt	cgaggtgccg	3720

taaagctcta aatcggaacc ctaaaggag ccccccgattt agagcttgac ggggaaagcc 3780  
ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcggcgctga gggcgctggc 3840  
aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc gcgcttaa 3888

<210> 27

<211> 4606

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:plasmid

<400> 27

tgcgcgcgcta cagggcgcgct ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60  
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120  
ttaagttggg taacgccagg gttttccag tcacgacgtt gtaaacgac ggccagtga 180  
ttgtaatacg actcactata gggcgaattg ggcccgacgt cgcgtgctcc cgcccgccat 240  
ggccgcggga tgcggcgcg tcgacgtgaa ataccgcaca gatgcgtaag gagaaaatac 300  
cgcatcaggc gataaaccca gcgaaccatt tgagggtgata ggtaagatta taccgaggta 360  
tgaaaacgag aattggacct ttacagaatt actctatgaa gcgccatatt taaaaagcta 420  
ccaagacgaa gaggatgaag aggatgagga ggcagattgc cttgaatata ttgacaatac 480  
tgataagata atatatcttt tatatagaag atatcgccgt atgtaaggat ttcagggggc 540  
aaggcatagg cagcgcgctt atcaatatat ctatagaatg ggcaaagcat aaaaacttgc 600  
atggactaat gcttgaaacc caggacaata acctatagc ttgtaaattc tatcataatt 660  
gtggtttcaa aatcggtctc gtcgatacta tgttatacgc caactttcaa aacaactttg 720  
aaaaagctgt tttctgggtt ttaagggttt agaatgcaag gaacagtga ttggagttcg 780  
tcttgttata attagcttct tgggggtatct ttaataactg tagaaaagag gaaggaaata 840  
ataaatggct aaaatgagaa tatcacccgga attgaaaaaa ctgatcgaaa aataccgctg 900  
cgtaaaagat acggaaggaa tgtctcctgc taagggtatat aagctgggtg gagaaaatga 960  
aaacctatat ttaaaaatga cggacagccg gtataaagg accacctatg atgtggaacg 1020  
ggaaaaggac atgatgctat ggctggaagg aaagctgcct gttccaaagg tccctgcaact 1080  
tgaacggcat gatggctgga gcaatctgct catgagttag gccgatggcg tcccttgctc 1140  
ggaagagtat gaagatgaac aaagccctga aaagattatc gagctgtatg cggagtgcac 1200  
caggctcttt cactccatcg acatatcgga ttgtccctat acgaatagct tagacagccg 1260  
cttagccgaa ttggattact tactgaataa cgatctggcc gatgtggatt gcgaaaactg 1320  
ggaagaagac actccattta aagatccgcg cgagctgtat gattttttta agacggaaaa 1380  
gcccgaagag gaacttgtct tttcccacgg cgacctggga gacagcaaca tctttgtgaa 1440  
agatggcaaa gtaagtggct ttattgatct tgggagaagc ggcagggcgg acaagtggta 1500  
tgacattgcc ttctgcgtcc ggtcgatcag ggaggatata ggggaagaac agtatgtcga 1560  
gctatttttt gacttactgg ggatcaagcc tgattgggag aaaataaaat attatatatt 1620  
actggatgaa ttgttttagt acctagattt agatgtctaa aaagctttta ctacaagctt 1680  
tttagacatc taatcttttc tgaagtacat ccgcaactgt ccatactctg atgttttata 1740  
tcttttctaa aagttcgcta gataggggtc ccgagcgctt acgaggaatt tgtatcgcca 1800  
ttcgccattc aggtcgcgca actgttgga agggcgatcg gtgcgggtac cgggatcact 1860  
agtgcggccg cctgcaggtc gaccatatgg gagagctccc aacgcgttgg atgcataget 1920  
tgagtattct atagtgtcac cttaaagct tggcgtaatc atggtcatag ctgtttcctg 1980  
tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgt 2040  
aagcctgggg tgcctaata gtagctaac tcacattaat tgcgttgcg tcaactgccc 2100  
ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga 2160  
gaggcggttt gcgtattggg cgctcttcct ctctctcgt cactgactcg ctgcgctcgg 2220  
tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 2280  
aatcagggga taacgcagga aagaacatgt gagcaaaaag ccagcaaaag gccaggaacc 2340  
gtaaaaaggc cgcgttgctg gcgtttttct ataggctcog ccccccgtac gagcatcaca 2400  
aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 2460  
ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc 2520  
tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc ttaggtatc 2580  
tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaacc cccgttcagc 2640  
ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccgggt agacacgact 2700  
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgagggtat gtaggcgggtg 2760

ctacagagtt	cttgaagtgg	tggcctaact	acggctacac	tagaaggaca	gtatttggtg	2820
tctgcgctct	gctgaagcca	gttaccttcg	gaaaaagagt	tggtagctct	tgatccggca	2880
aacaaaccac	cgctggtagc	ggtggttttt	ttgtttgcaa	gcagcagatt	acgcgcagaa	2940
aaaaaggatc	tcaagaagat	cctttgatct	tttctacggg	gtctgacgct	cagtggaaacg	3000
aaaactcacg	ttaagggatt	ttgggtcatga	gattatcaaa	aaggatcttc	acctagatcc	3060
ttttaaat	aaaatgaagt	tttaaatcaa	tctaaagtat	atatgagtaa	acttgggtctg	3120
acagttacca	atgcttaatc	agtgaaggcac	ctatctcagc	gatctgtcta	tttcgttcat	3180
ccatagttgc	ctgactcccc	gtcgtgtaga	taactacgat	acgggagggc	ttaccatctg	3240
gccccagtg	tgcaatgata	ccgcgagacc	cacgctcacc	ggctccagat	ttatcagcaa	3300
taaaccagcc	agccggaagg	gccgagcgca	gaagtgggtc	tgcaacttta	tccgcctcca	3360
tccagctctat	taattgttgc	cgggaagcta	gagtaagtag	ttcgcaggtt	aatagtttgc	3420
gcaacgttgt	tggcattgct	acaggcatcg	tgggtgtcag	ctcgtcggtt	ggtatggctt	3480
cattcagctc	cggttcccaa	cgatcaaggc	gagttacatg	atcccccatg	ttgtgcaaaa	3540
aagcggttag	ctccttcggt	cctccgatcg	ttgtcagaag	taagttggcc	gcagtgttat	3600
cactcatggt	tatggcagca	ctgcataatt	ctcttactgt	catgccatcc	gtaagatgct	3660
tttctgtgac	tggtagtac	tcaaccaagt	cattctgaga	ataccgcgcc	cggcgaccga	3720
gttgctcttg	cccggcgctc	atacgggata	atagtgtatg	acatagcaga	actttaaaag	3780
tgctcatcat	tggaaaacgt	tcttcggggc	gaaaactctc	aaggatctta	ccgctgttga	3840
gatccagttc	gatgtaacce	actcgtgcac	ccaactgac	ttcagcatct	tttactttca	3900
ccagcgtttc	tgggtgagca	aaaacaggaa	ggcaaaaatg	cgcaaaaaag	ggaataaggg	3960
cgacacggaa	atgttgtaata	ctcatactct	tcctttttca	atattattga	agcattttatc	4020
agggttattg	tctcatgagc	ggatacatat	ttgaatgtat	ttagaaaaat	aaacaaatag	4080
gggttcgcgc	cacatttccc	cgaaaagtgc	cacctgtatg	cgggtgtgaa	taccgcacag	4140
atgcgtaagg	agaaaatacc	gcatcaggcg	aaattgtaaa	cgttaatatt	ttgttaaaaat	4200
tcgcgttaaa	tatttgttaa	atcagctcat	tttttaacca	ataggccgaa	atcggcaaaa	4260
tcccttataa	atcaaaaaga	tagaccgaga	tagggttgag	tgttgttcca	gtttggaaca	4320
agagtccact	attaaagaac	gtggactcca	acgtcaaagg	gcgaaaaacc	gtctatcagg	4380
gcgatggccc	ccatcagtaa	ccatcaccca	aatcaagttt	tttgcggtcg	aggtgccgta	4440
aagctctaaa	tcggaaccct	aaaggagacc	ccgatttag	agcttgacgg	ggaaagccgg	4500
cgaacgtggc	gagaaaggaa	gggaagaaag	cgaaaggagc	gggcgctagg	gcgctggcaa	4560
gtgtagcggg	cacgctgcgc	gtaaccacca	caccgcgcgc	gcttaa		4606

&lt;210&gt; 28

&lt;211&gt; 5399

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:plasmid

&lt;400&gt; 28

tgccgcgcta	cagggcgcg	ccattcgcca	ttcaggctgc	gcaactgttg	ggaagggcga	60
tcgggtgcgg	cctcttcgct	attacgccag	tttgggggtg	agttcatgaa	gtttcgtcgc	120
agcggcagat	tgggtgactt	aacaaattat	ttgttaaccc	atccgcacga	gttaataaccg	180
ctaacccttt	tctctgagcg	gtatgaatct	gcaaaatcat	cgatcagtag	agatttaaca	240
attattaaac	aaacctttga	acagcagggg	attggtactt	tgcttactgt	tcccgagact	300
gccggaggcg	ttaaatatat	tccgaaaatg	aagcaggctg	aagctgaaga	gtttgtgcag	360
acacttggac	agtcgctggc	aaatcctgag	cgtatccttc	cggcggttga	tgtatattta	420
acggatatct	taggaaagcc	atctgtactc	tccaaggtag	ggaagctgtt	tgcttccgtg	480
tttgacagag	gcgaaattga	tgttgtcatg	accgttgcca	cgaaaggcat	ccctcttgcg	540
tacgcagctg	cggccgcgtc	gacaaacca	gtgaaccatt	tgaggtgata	ggtaagatta	600
taccgaggta	tgaaaacgag	aattggacct	ttacagaatt	actctatgaa	gcgccatatt	660
taaaaagcta	ccaagacgaa	gaggatgaag	aggatgagga	ggcagattgc	cttgaatata	720
ttgacaatac	tgataagata	atatatcttt	tatatagaag	atatcgccgt	atgtaaggat	780
ttcagggggc	aaggcatagg	cagcgcgctt	atcaatatat	ctatagaatg	ggcaaagcat	840
aaaaacttgc	atggactaat	gcttgaaacc	caggacaata	accttatagc	ttgtaaaattc	900
tatcataatt	gtggtttcaa	aatcggctcc	gtcgatacta	tgttatacgc	caactttcaa	960
aacaactttg	aaaaagctgt	tttctgggtat	ttaaggtttt	agaatgcaag	gaacagtgaa	1020
ttggagtctg	tcttgttata	attagcttct	tgggggtatct	ttaaatactg	tagaaaagag	1080

gaaggaaata ataaatggct aaaatgagaa tatcaccgga attgaaaaaa ctgatcgaaa 1140  
aataccgctg cgtaaaagat acggaaggaa tgtctcctgc taaggatatat aagctgggtg 1200  
gagaaaatga aaacctatat ttaaaaatga cggacagccg gtataaaggg accacctatg 1260  
atgtggaacg ggaaaaggac atgatgctat ggctggaagg aaagctgcct gttccaaagg 1320  
tcctgcactt tgaacggcat gatggctgga gcaatctgct catgagttag gccgatggcg 1380  
tcctttgctc ggaagagtat gaagatgaac aaagccctga aaagattatc gagctgtatg 1440  
cggagtgcac caggctcttt cactccatcg acatatcgga ttgtccctat acgaatagct 1500  
tagacagccg cttagccgaa ttggattact tactgaataa cgatctggcc gatgtggatt 1560  
gcgaaaactg ggaagaagac actccattta aagatccgog cgagctgtat gattttttaa 1620  
agacggaata gccgaagag gaacttgtct ttcccaacgg cgacctggga gacagcaaca 1680  
tcctttgtgaa agatggcaaa gtaagtggct ttattgatct tgggagaagc ggcagggcgg 1740  
acaagtggta tgacattgcc ttctgcgtcc ggtcgatcag ggaggatata ggggaagaac 1800  
agtatgtcga gctatTTTTT gacttactgg ggatcaagcc tgattgggag aaaataaaat 1860  
attatatTTT actggatgaa ttgttttagt acctagattt agatgtctaa aaagctttaa 1920  
ctacaagctt tttagacatc taatcttttc tgaagtacat ccgcaactgt ccatactctg 1980  
atgttttata tcttttctaa aagttcgcta gataggggtc ccgagcgccct acgaggaatt 2040  
tgtatcacca ggtaccagct gcaagctatt tgaatgtgcc tgttgtgatc gttcgtaaag 2100  
acaataaggt aacagagggc tccacagtca gcattaatta cgtttcaggc tcctcaaacc 2160  
gcattcaaac aatgtcactt gcgaaaagaa gcatgaaaac gggttcaaac gtactcatta 2220  
ttgatgactt tatgaaagca ggcggcacca ttaatgggtat gattaacctg ttggatgagt 2280  
ttaacgcaaa tgtggcggga atcggcgctc tagttgaagc cgaaggagta gatgaacgtc 2340  
ttgttgacga atatatgtca cttcttactc tttcaaccat caacatgaaa gagaagtcca 2400  
ttgaaattca gaatggcaat tttctgcgtt tttttaaaga caatctttta aagaatggag 2460  
agacagaatc atgacaaaag cagtccacac aaaacatgcc ccagcggcaa tcgggcctta 2520  
ttcacaaggg attatcgtca acaatatgtt ttacagctca ggccaaatcc ctttgactcc 2580  
ttcaggcgaa atgggtgaatg gcgatattaa ggagcagact catcaagtat tcagcaattt 2640  
aaaggcgggt ctggaagaag cgggtgcttc ttttgaaaaca gttgtaaaag caactgtatt 2700  
tatcgcggat atggaacagt ttgcggaaat aaacggaagt tacggacaat attttgacac 2760  
tcacaaaccg gcgagatctt tggttgaagt cgcgagactc ccgaaggatg cgttagtcga 2820  
gatcgaagtt attgcaactg tgaataata agaaaagtga ttctgggaga gccgggatca 2880  
cttttttatt taccttatgc ccgaaatgaa agctttatga ccctgcatta atgaatcggc 2940  
caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttccct gctcaactgac 3000  
tcgctgcgct cggctcgttcg gctgcggcga cgcgtatcag ctcaactcaa ggcggttaata 3060  
cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa 3120  
aaggccagga accgtaaaaa ggccgcgttg ctggcgcttt tcgataggct ccgccccct 3180  
gacgagcatc acgctcaagt cagaggtggc caagcccgac aggactataa 3240  
agataccagg cgtttccccc tggaaagctc ctctgctgct ctctgttcc gacctgccg 3300  
cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca 3360  
cgctgtagggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa 3420  
cccccgctt agcccgaccg ctgcgcctta tccggttaact atcgtcttga gtccaacccg 3480  
gtaagacacg acttatcgcc actggcagca gccactggta acaggattag cagagcgagg 3540  
tatgtaggcg gtgctacaga gttcttgaag tgggtggccta actacggcta cactagaagg 3600  
acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc 3660  
tcttgatccg gcaaaacaaac caccgtgggt agcgggtggt tttttgtttg caagcagcag 3720  
attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac 3780  
gctcagtggg acgaaaactc acgttaaggg attttgggtca tgagattatc aaaaaggatc 3840  
ttcacctaga tcctttttaa ttaaaaatga agtttttaaat caatctaaag tatatatgag 3900  
taaacttgggt ctgacagtta ccaatgctta atcagttagg cacctatctc agcgatctgt 3960  
ctatttctgt catccatagt tgcctgactc cccgtcggtg agataactac gatacgggag 4020  
ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca 4080  
gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact 4140  
ttatccgctt ccatccagtc tattaattgt tgccgggaag cttagagtaag tagttcgcca 4200  
gttaatatgt tgcgcaacgt tgttggcatt gctacaggca tcgtgggtgc acgctcgtcg 4260  
tttggtagtg cttcatttcag ctccggttcc caacagatcaa ggcgagttac atgatcccc 4320  
atgttgtgca aaaaagcgggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg 4380  
gccgcagtgt tatcactcat gggtatggca gcaactgcata attctcttac tgtcatgcca 4440  
tcogtaagat gcttttctgt gactgggtgag tactcaacca agtcattctg agaataccgc 4500  
gcccggcgac cgagttgctc ttgcccggcg tcaatacggg ataatagtgt atgacatagc 4560  
agaactttaa aagtgtcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc 4620



ttaccgctgt tgagatccag ttccgatgtaa cccactcgtg caccacaactg atcttcagca 4680  
tctttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa 4740  
aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat 4800  
tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa 4860  
aataaaca aa taggggttcc gcgcacattt ccccgaaaag tgccacctgt atgcgggtgtg 4920  
aaataccgca cagatgcgta aggagaaaaat accgcatcag gcgaaattgt aaacgttaat 4980  
attttgttaa aattcgcgtt aaatatattgt taaatcagct cattttttta ccaataggcc 5040  
gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt 5100  
ccagtttga acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa 5160  
accgtctatc agggcgatgg cccactacgt gaaccatcac ccaaatacaag ttttttgcgg 5220  
tcgagggtcc gtaaaagtct aaatcggaac cctaaaggga gccccgatt tagagcttga 5280  
cggggaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct 5340  
agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacaccgc cgcgcttaa 5399

<210> 29

<211> 6805

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 29

ttgcggccgc ttccgaaagct gtaatatataa aaccttcttc aactaacggg gcagggttagt 60  
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120  
tcattaggcc tatctgacaa ttccctgaata gatttcataa acaatcctgc atgataacca 180  
tcacaaacag aatgatgtac ctgtaaaagt agcggtaaat atattgaatt acctttatta 240  
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300  
ttaaaccag taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata 360  
ggtgttttgg gaaacaattt ccccgaaacca ttatatctct ctacatcaga aagggtataaa 420  
tcataaaact ctttgaagtc attctttaca ggagtcctaaa taccagagaa tgtttttagat 480  
acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg 540  
ctattgtaac cagttctaaa agctgtattt gaggtttatca cccttgtcac taagaaaata 600  
aatgcagggt aaaattttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660  
atcttctgtg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720  
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaattttt 780  
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840  
taaaagtcaa tattactgta acataaatat atatttttaa aatatcccac tttatccaat 900  
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960  
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020  
tgataataag ggtaaactatt gaattcggta ccaagagttt gtagaaacgc aaaaaggcca 1080  
tccgtcagga tggccttctg cttaatttga tgcctggcag tttatggcgg gcgtcctgcc 1140  
cgccaccctc cgggcccgtt cttcgcaacg ttcaaactcg ctcccggcgg atttgtccta 1200  
ctcaggagag cgttcaccga caaacaacag ataaaacgaa aggccagtc tttcgactga 1260  
gcctttcggt ttatttgatg cctggcagtt ccctactctc gcatggggag accccacact 1320  
accatcggcg ctacggcgtt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380  
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgcgttctg atttaatctg 1440  
tatcaggctg aaaatcttct ctcatccgcc aaaacaggat ccaattatgg cagatcaatg 1500  
agcttcacag acacaatatc agggacattt gttagttctt tcacaatttt atcttcaga 1560  
tgtctgtcaa aggaaagcat catgatggct tctccgcctt tttccttacg gccaacctgc 1620  
atagttgcaa tgtaaatatc attatctccg agaatacgtc ctactcggcc gatgacacct 1680  
gttgtatctt gatgctggat atacaccaag tgaccagtcg gataaaaatc aatattaaat 1740  
ccattgatct cgacaattcg ttctccgaaa tgaggaatat acgtagccgt tacagtaaag 1800  
gtgctgcggt ctctgtcac ttttacgctg ttccagttat cgtatccaga ttcagaagag 1860  
gaaatttttt cactgaagct aatgccgcgt tcttttgcga ccccccgcc attgacctca 1920  
ttaacagtag agtctacgcg cggtttttaa aagcctgaca gaagggttt tgtaatgaac 1980  
gatgtttcaa gtttagcaat tgtgccttca tattgaatgg caacatcctg tactggttct 2040  
ttcatgcact gtgatacaag gctgccaat tttcctgcaa tttgatggta aggccttaatt 2100  
ttagcaaat catcttttgt catggcaggc aggttgatag ctgacatgac aggcaggcct 2160



tttgcgaact gcagaacttc ttctgacact tgggcggcga cattgagctg tgcttctttc 2220  
gttgatgctc ccaagtggagg agtggcaatg actaatggat gatcaacaag tttgttgta 2280  
actggcgggt cgacttcgaa aacgtcaagc gctgctcccg caacatgcc gttttccaaa 2340  
gcttcgagaa gtgctgcttc atcgataatt ccgcctcgcg cacagttaat taagcgaacg 2400  
ccttttttcg tttttgcaat cgtttcttta ttcaataagc cttttgtttc ttttggtaaa 2460  
ggcgtgtgaa cggtaatgat atccgcactt tcaagcactt cttcaaattgt acggctgttt 2520  
acgccgattt ttttcgctct ttcttcggtt aagaaaggat caaaaacgtg cacagtcata 2580  
ccgaacgctc ctgcagcgtg tgcaatttca cttccgattc ggctaatacc tacaatacca 2640  
agcgtttttc cataaagctc tgaaccgaca taagctgtgc ggttccactc tctggatttc 2700  
actgagatat tagcctgctg aatgtgtctc attaaagaag agatcattgc aaatgtatgc 2760  
tcagctgtcg aaatggtgtt gccgttcgga gcattgatca cgattacccc gtgtttcgta 2820  
gcctcatcaa tatcgatatt atcgacaccg acaccggctc ttccgacaat ttttaaagaa 2880  
gtcattttgt tgaaaaggct ttctgttact tttgtcgcg ttcgcaccaa aagagcatca 2940  
aaagtatgta attcatcttc tgcactctgt acgttttttt gaacgatttc aataaagtct 3000  
gattcaataa gtggctgtaa accgtcgttg ctcattttgt ctgagaccaa tactcgaaac 3060  
atgtttttct ctcctctaga gcgtcctgtt gttgttaaga ttattatacc acaccttgta 3120  
gataaagtca acaacttttt gcaaaatttt tcaggaattt tagcagaggt tgttctggat 3180  
gtagaacaaa acacttttc gctctgtgc tttaggata tctttcttgg aagctaggta 3240  
ggcctcgagt tatggcagtt gggtaaaagg aaacaaaagg accgttttca cacaaaacgg 3300  
tctttttcga tttcttttta cagtcacagc cacttttgca aaaaccggac agcttcatgc 3360  
cttataactg ctgtttcggg cgacctgcag gcatgcaagc ttcgcgagc ggccgccgac 3420  
gcgaggctgg atggccttcc ccattatgat tcttctcgct tccggcggca tcgggatgcc 3480  
cgctgtgcag gccatgctgt ccaggcaggt agatgacgac catcagggac agcttcaagg 3540  
atcgctcgcg gctcttacca gcctaacttc gatcactgga ccgctgatcg tcacggcgat 3600  
ttatgccgcc tcggcgagca catggaacgg gttggcatgg attgtaggcg ccgccctata 3660  
ccttgtctgc ctccccgct tgctcgcg taacggatcc accactcaa gaattggagc caatcaattc 3720  
ggaagccggc ggcacctgc taacggatcc accactcaa gaattggagc caatcaattc 3780  
ttgcggagaa ctgtgaatgc gcaaaccaac ccttggcaga acatatccat cgcgtccgcc 3840  
atctccagca gccgcacgcg ggcactctcg ggcagcgttg ggtcctggcc acgggtgcgc 3900  
atgatcgtgc tctgtctgtt gaggaccggg ctaggctggc ggggttgcc tactggttag 3960  
cagaatgaat caccgatacg cgagcgaacg tgaagcgact gctgctgcaa aacgtctgcg 4020  
acctgagcaa caacatgaat ggtcttcggg ttccgtgttt cgtaaagtct ggaaacgcgg 4080  
aagtacgcgc cctgcacat tatgttccgg atctgcatcg caggatgctg ctggctaccc 4140  
tgtggaacac ctacatctgt attaacgaag cgctggcatt gaccctgagt gatttttctc 4200  
tggtcccgc gcacccatct cgccagttgt ttaccctcac aacgttccag taaccgggca 4260  
tgttcacat catgaaccgc tatcgtgagc atcctctctc gtttcatcgg tatcattacc 4320  
cccatgaaca gaaattcccc cttacacgga ggcatcaagt gaccaaacag gaaaaaacg 4380  
cccttaacat ggcccgcttt atcagaagcc agacattaac gcttctggag aaactcaacg 4440  
agctggacgc ggatgaacag gcagacatct gtgaatcgct tcacgaccac gctgatgagc 4500  
tttaccgcag ctgcctcgcg cgtttcgggt atgacggtga aaacctctga cacatgcagc 4560  
tcccggagac ggtcacagct tgtctgtaag cggtatgccg gagcagacaa gcccgtcagg 4620  
gcgcgtcagc ggggtgttggc ggggtgtcggg gcgcagccat gaccagtcg cgtagcgata 4680  
gcggagtgt tactggctta actatgcggc atcagagcag attgtactga gagtgcacca 4740  
tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggcgtcttc 4800  
cgcttctcg ctcaactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc 4860  
tcaactcaag gcggtaatat ggttatccac agaatacagg gataacgcag gaaagaacat 4920  
gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt 4980  
ccataggctc cgccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg 5040  
aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc 5100  
tctgttccg accctgccgc ttaccggata cctgtccgcc ttttctccct cgggaagcgt 5160  
ggcgttttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa 5220  
gctgggctgt gtgcacgaac ccccgttca gcccagccgc tgcgccttat ccggtacta 5280  
tcgtcttgag tccaacccgg taagacacga cttatcgcca ctggcagcag cactggtaa 5340  
caggattag agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa 5400  
ctacggctac actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt 5460  
cggaaaaaga gttggtagct cttgatccgg caaacaacc accgctggtg gcggtgggtt 5520  
ttttgtttgc aagcagcaga ttacgcgcag aaaaaaggga tctcaagaag atcctttgat 5580  
cttttctacg gggctctgacg ctacgtggaa cgaaaactca cgtaaaggga ttttggctat 5640  
gagattatca aaaaggatct tcacctagat ctttttaaat taaaaatgaa gttttaaatc 5700

```

aatctaaagt atatatgagt aaacttgggtc tgacagttac caatgcttaa tcagtggagg 5760
acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta 5820
gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga 5880
cccacgtca cgggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg 5940
cagaagtggg cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc 6000
tagagtaagt agttcgccag ttaatagttt gcgcaacggt gttgccattg ctgcaggcat 6060
cgtgggtgtca cgctcgtcgt ttggtatggc ttcattcagc tccggttccc aacgatcaag 6120
gcgagttaca tgatcccca tgttgtgcaa aaaagcgggt agctccttcg gtccctccgat 6180
cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa 6240
ttctcttact gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa 6300
gtcattctga gaatagtgtg tgcggcgacc gagttgctct tgcccggcgt caatacggga 6360
taataccgcg ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg 6420
gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccaactcgtgc 6480
acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg 6540
aaggcaaaat gccgcaaaaa aggggaataag ggcgacacgg aaatggtgaa tactcatact 6600
cttccttttt caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat 6660
atltgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt 6720
gccacctgac gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat 6780
cacgaggccc tttcgtcttc aagaa

```

<210> 30

<211> 5983

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 30

```

tgcgcgcta cagggcggt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac ggccagtga 180
ttgtaatacg actcactata gggcgaattg ggcccagcgt cgcattgctc cggccgccat 240
ggccgcggga tatcactagt gcggccgcct gcaggtcgac catatgggag agcccgatc 300
caattatggc agatcaatga gcttcacaga cacaatatca gggacatttg ttagttcctt 360
cacaatttta tcttcagat gtctgtcaaa ggaaagcatt atgatggctt ctccgccttt 420
ttccttacgg ccaacctgca tagttgcaat gttaatatca ttatctccga gaatacgtcc 480
tactcggccg atgacacctg ttgtatcttg atgctggata tacaccaagt gaccagtcgg 540
ataaaaaatc atattaaatc cattgatctc gacaattcgt tctccgaaat gaggaatata 600
cgtagccgtt acagtaaagg tgctgcggtc tcctgtcact tttacgctga tgcagttatc 660
gtatccagat tcagaagagg aaattttttc actgaagcta atgccgcgtt cttttgcgac 720
acccccggca ttgacctcat taacagtaga gtctacgcgc ggttttaaaa agcctgacag 780
aagggtcttt gtaatgaacg atgtttcaag tttagcaatt gtgccttcatt attgaatggc 840
aacatcctgt actggttctt tcatgcactg tgatacaagg ctgccaattt ttctgcaat 900
ttgatggtaa ggcttaattt tagcaaatc atcttttgtc atggcaggca ggttgatagc 960
tgacatgaca ggcaggcctt ttgcgaactg cagaacttct tctgacactt gggcggcgac 1020
attgagctgt gcttctttcg ttgatgctcc caagtgagga gtggcaatga ctaatggatg 1080
atcaacaagt ttgttgtcaa ctggcggttc gacttcgaaa acgtcaagcg ctgctcccgc 1140
aacatgcccg ttttccaaag ctttttagac atctaaatct aggtactaaa acaattcatc 1200
cagtaaaata taatatttta ttttctccca atcaggcttg atccccagta agtcaaaaaa 1260
tagctcgaca tactgttctt ccccgatata ctccctgate gaccggagcg agaaggcaat 1320
gtcataccac ttgtccgccc tgccgcttct cccaagatca ataaagccac ttactttgcc 1380
atctttcaca aagatgttgc tgtctcccag gtcgcggtg gaaaagacaa gttcctcttc 1440
gggcttttcc gtctttaaaa aatcatacag ctgcgcggga tctttaaatg gagtgtcttc 1500
ttcccagttt tcgcaatcca catcgccag atcggtattc agtaagtaat ccaattcggc 1560
taagcggctg tctaagctat tcgtataggg acaatccgat atgtcgatg agtgaaagag 1620
cctgatgcac tccgcataca gctcgataat cttttcaggg ctttgttcatt cttcatactc 1680
ttccgagcaa aggacgcat cggcctcact catgagcaga ttgctccagc catcatgccg 1740
ttcaaagtgc aggacctttg gaacaggcag ctttcttcc agccatagca tcatgtcctt 1800

```

ttcccgttcc acatcatagg tgggtcccttt ataccggctg tccgtcattt ttaaataatag 1860  
gttttcattt tctcccacca gcttatatac cttagcagga gacattcctt ccgtatcttt 1920  
tacgcagcgg tatttttctga tcagtttttt caattccggg gatattctca ttttagccat 1980  
ttattatttc cttcctcttt tctacagtat ttaaagatac cccaagaagc taattataac 2040  
aagacgaact ccaattcact gttccttgca ttctaaaacc ttaaatacca gaaaacagct 2100  
ttttcaaagt tgttttgaaa gttggcgat aacatagtat cgacggagcc gattttgaaa 2160  
ccacaattat gatagaattt acaagctata aggttattgt cctgggtttc aagcattagt 2220  
ccatgcaagt ttttatgctt tgcccattct atagatatat tgataagcgc gctgcctatg 2280  
ccttgccccc tgaaatcctt acatacggcg atatcttcta tataaaagat atattatctt 2340  
atcagtattg tcaatatatt caaggcaata tgcctctca tctcttcat cctcttcgtc 2400  
ttggtagctt tttaaatatg gcgcttcata gagttaattct gtaaagggtcc aattctcgtt 2460  
ttcatacctc ggtataatct tacctatcac ctcaaagggt tcgctgggtt tatcgctga 2520  
tgcggtattt tctccttacg catctgtgcg gtatttcacg tcgacgcggc cgccatggcc 2580  
gcgggatccc ggtaccgaaa catcgtaga ttctctcta aattgacaaa ctaaatactt 2640  
gataatttaa catattctca aaagagtgtc aacgtgtatt gacgcagtaa aggataaaaag 2700  
taaagcctaa taaatcaatg atctgacagc ttgcaggtaa tatatttaat ttgaagcaat 2760  
tctctataca gcccaaccagt tatcgtttat aatgtaatta aatttcatat gatcaatctt 2820  
cggggcaggg tgaaattccc taccggcggg gatgagccaa tggctctaag cccgcgagct 2880  
gtcttttacg caggattcgg tgagattccg gagccagacg tacagtctgg atgggagaag 2940  
atggagggtt ataagcggtt tgaaattgaa ttttccaac gtttctttgc ctagcctaata 3000  
tttcgaaaacc ccgcttttat atatgaagcg gtttttttat tggctggaaa agaacccttc 3060  
cgttttcgag taagatgtga tcgaaaagga gagaatgaag tgaaagtaaa aaaattagtt 3120  
gtggctcagca tgctgagcag cattgcattt gttttgatgc tgttaaattt cccgtttccg 3180  
ggctctccgg attattttaa aatcgatttt agcgacgttc ccgcaattat tgccattctg 3240  
atttacggac ctttgccggg atcactagag ggctcccaac gcgttggtat catagcttga 3300  
gtattctata gtgtcaccta aatagcttgg cgtaatcatg gtcatagctg tttcctgtgt 3360  
gaaattgtta tccgctcaca attccacaca acatacagc cggaagcata aagtgtaaat 3420  
cctgggggtg ctaatagtg agctaactca cattaattgc gttgcgctca ctgcccggct 3480  
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag 3540  
gcggtttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg cgctcggtcg 3600  
ttcggtcgcg gcgagcggta tcagctcact caaaggcggg aatacggtta tccacagaat 3660  
caggggataa cgcaggaaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 3720  
aaaaggccgc gttgctggcg tttttcgata ggctccgccc ccctgacgag catcacaaaa 3780  
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 3840  
cccttgaag ctcctcctg cgctctctg ttccgacctt gccgcttacc ggatacctgt 3900  
ccgctttct ccttcggga agcgtggcg tttctcatag ctcacgctgt aggtatctca 3960  
gttcggtgta ggtogttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagcccg 4020  
accgctgcgc cttatccggg aactatcgtc ttgagtccaa cccggtaaga cacgacttat 4080  
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 4140  
cagagttctt gaagtgggtg cctaactacg gctacactag aaggacagta tttggtatct 4200  
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 4260  
aaaccaccgc tggtagcggg gttttttttg tttgcaagca gcagattacg cgcagaaaaa 4320  
aaggatctca agaagatcct ttgatctttt ctacgggggtc tgacgctcag tggaacgaaa 4380  
actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt 4440  
taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggctgaca 4500  
gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt cgttcatcca 4560  
tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggtta ccatctggcc 4620  
ccagtgtgc aatgataccg cgagaccac gctcaccggc tccagattta tcagcaataa 4680  
accagccagc cggaagggcc gagcgagaa gtggctcctg aactttatcc gcctccatcc 4740  
agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 4800  
acgttgttgg cattgctaca ggcacgtgg tgctacgctc gtcgtttggg atggcttcat 4860  
tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag 4920  
cgttagctc cttcggctct ccgatcgtt tcaagaagtaa gttggccgca gtgttatcac 4980  
tcattggtat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 5040  
ctgtgactgg tgagtactca accaagtcac tctgagaata ccgcgcccgg cgaccgagtt 5100  
gctcttgccc ggcgtcaata cgggataata gtgtatgaca tagcagaact ttaaaagtgc 5160  
tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat 5220  
ccagttcgat gtaaccact cgtgcacca actgatcttc agcatctttt actttcacca 5280  
gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaggga ataaggcgca 5340

```
cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 5400
gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 5460
ttccgcgcac atttcccga aaagtgccac ctgtatgcgg tgtgaaatac cgcacagatg 5520
cgtaaggaga aaataccgca tcaggcgaaa ttgtaaacgt taatattttg ttaaaattcg 5580
cgttaaatat ttgttaaate agctcatttt ttaaccaata ggccgaaatc ggcaaaatcc 5640
cttataaatc aaaagaatag accgagatag ggttgagtgt tgttccagtt tggaacaaga 5700
gtccactatt aaagaacgtg gactccaacg tcaaagggcg aaaaaccgtc tatcagggcg 5760
atggcccact acgtgaacca tcacccaaat caagtttttt gcggtcgagg tgccgtaaag 5820
ctctaaatcg gaaccctaaa gggagccccc gatthagagc ttgacgggga aagccggcga 5880
acgtggcgag aaaggaaggg aagaaagcga aaggagcggg cgctagggcg ctggcaagtg 5940
tagcggtcac gctgcgcgta accaccacac ccgcccgcgt taa 5983
```

&lt;210&gt; 31

&lt;211&gt; 7330

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: plasmid

&lt;400&gt; 31

```
ttgcggccgc ttcgaaagct gtaatatataa aaccttcttc aactaacggg gcaggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttcctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaacccag taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcagggtata 360
ggtgttttgg gaaacaattt ccccgaacca ttatatttct ctacatcaga aagggtataaa 420
tcataaaact ctttgaagtc attctttaca ggagtccaaa taccagagaa tgttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca cccttgtcac taagaaaata 600
aatgcagggt aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaattttt 780
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atattttaaa aatatccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggta ccaagagttt gtagaaacgc aaaaaggcca 1080
tcogtcagga tggccttctg cttaatttga tgcctggcag tttatggcgg gcgtcctgcc 1140
cgccaccctc cgggccgttg cttcgcaacg ttcaaaccg ctcccggcgg atttgtccta 1200
ctcaggagag cgttcaccga caaacaacag ataaaacgaa aggcccagtc tttcgactga 1260
gcctttcgtt ttatttgatg cctggcagtt ccctactctc gcatggggag accccacact 1320
accatcgcg ctagcggtt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgcgttctg atttaatctg 1440
tatcaggctg aaaatcttct ctcacccgcc aaaacaggat ccaattatgg cagatcaatg 1500
agcttcacag acacaatatc agggacattt gttagttctt tcacaatttt atcttccaga 1560
tgtctgtcaa aggaaagcat catgatggct tctccgcctt tttccttacg gccaacctgc 1620
atagttgcaa tgttaatatc attatctccg agaatacgtc ctactcggcc gatgacacct 1680
gttgatctct gatgctggat atacaccaag tgaccagtcg gataaaaatc aatattaaat 1740
ccattgatct cgacaattcg ttctccgaaa tgaggaatat acgtagccgt tacagtaaag 1800
gtgctgcggg ctctgtcac ttttacgctg atgcagttat cgtatccaga ttcagaagag 1860
gaaatttttt cactgaagct aatgccgcgt tcctttgcga ccccccgcc attgacctca 1920
ttaacagtag agtctacg cggtttttaa aagcctgaca gaagggtttt tgtaatgaac 1980
gatgtttcaa gtttagcaat tgtgccttca tattgaatgg caacatcctg tactggttct 2040
ttcatgcact gtgatacaag gctgccaat tttcctgcaa tttgatggta aggcttaatt 2100
ttagcaaat catcttttgt catggcaggc aggttgatag ctgacatgac aggcaggcct 2160
tttgcaact gcagaacttc ttctgacact tgggcggcga cattgagctg tgcttctttc 2220
gttgatgctc ccaagtgagg agtggcaatg actaatggat gatcaacaag tttgttgtca 2280
```

actggcggtt cgacttcgaa aacgtcaagc gctgctcccg caacatgcc gttttccaaa 2340  
gcttcgagaa gtgctgcttc atcgataatt ccgcctcgcg cacagttaat taagcgaacg 2400  
ccttttttcg tttttgcaat cgtttcttta ttcaataagc cttttgtttc ttttgtaaaa 2460  
ggcgtgtgaa cggtaatgat atccgcactt tcaagcactt cttcaaatgt acggctgttt 2520  
acgccgattt ttttcgctct ttcttccggt aagaaaggat caaaaacgtg cacagtcata 2580  
ccgaacgctc ctgcacgctg tgcaatttca cttccgattc ggcctaatac tacaatacca 2640  
agcgtttttc cataaagctc tgaaccgaca taagctgtgc ggttccactc tctggatttc 2700  
actgagatat tagcctgctg aatgtgtctc attaaagaag agatcattgc aaatgtatgc 2760  
tcagctgtcg aaatggtgtt gccgttcgga gcattgatca cgattacccc gtgtttcgta 2820  
gcctcatcaa tatcgatatt atcgacaccg acaccggctc ttccgacaat ttttaaagaa 2880  
gtcattttgt tgaaaaggct ttctgttact tttgtcgcg ttccgaccaa aagagcatca 2940  
aaagtatgta attcatcttc tgcatctgct acgttttttt gaacgatttc aataaagtct 3000  
gattcaataa gtggctgtaa accgtcgttg ctcattttgt ctgagaccaa tactcgaaac 3060  
atgttttctc ctctctaga gcgtcctgct gttgttaaga ttattatacc acaccttgta 3120  
gataaagtca acaacttttt gcaaaatttt tcaggaattt tagcagaggt tgttctggat 3180  
gtagaacaaa acatcttttc gctcttgtgc tgttaggata tctttcttgg aagctaggt 3240  
ggcctcgagt tatggcagtt ggttaaaaag aaacaaaaag accgttttca cacaaaacgg 3300  
tctttttcga tttcttttta cagtcacagc cacttttgca aaaaccggac agcttcatgc 3360  
cttataactg ctgttttcggt cgacgaaaca tcgttagatt tcctcctaaa ttgacaaact 3420  
aaatatctga taatttaaca tattctcaaa agagtgtcaa cgtgtattga cgcagtaaa 3480  
gataaaaagta aagcctaata aatcaatgat ctgacagctt gcaggtataa tatttaattt 3540  
gaagcaattc tctatacagc caaccagtta tcgtttataa tgtaattaaa tttcatatga 3600  
tcaatcttcg gggcagggtg aaattcccta ccggcggtga tgagccaatg gctctaagcc 3660  
cgcgagctgt ctttacagca ggattcgggt agattccgga gccgacagta cagtctggat 3720  
gggagaagat ggaggttcat aagcgttttg aaattgaatt tttcaaactg ttttttgcct 3780  
agcctaattt tcgaaacccc gcttttatat atgaagcggg ttttttattg gctggaaaa 3840  
aaccttttcg ttttcgagta agatgtgatc gaaaaggaga gaatgaagt aaagtaaaaa 3900  
aattagttgt ggtcagcatg caagcttcgc gaagcgccg cgcagcgag gctggatggc 3960  
cttccccatt atgattcttc tcgcttcggt cggcatcggt atgcccgcgt tgcaggccat 4020  
gctgtccagg caggtagatg acgaccatca gggacagctt caaggatcgc tcgcggtct 4080  
taccagccta acttcgatca ctggaccgct gatcgtcacg gcgatttatg ccgcctcggt 4140  
gagcacatgg aacgggttgg catggattgt aggcgcgccc ctataccttg tctgcctccc 4200  
cgcggttgcg cgcggtgcat ggagccgggc cacctcgacc tgaatggaag ccggcgccac 4260  
ctcgctaacg gattcaccac tccaagaatt ggagccaatc aattcttgcg gagaactgtg 4320  
aatgcgcaaa ccaacccttg gcagaacata tccatcgctt ccgccatctc cagcagccgc 4380  
acgcggcgca tctcgggcag cgttgggtcc tggccacggg tgcgcatgat cgtgctcctg 4440  
tcgttgagga ccggctagg ctggcggggt tgccctactg gtttagcagaa tgaatcaccg 4500  
atacgcgagc gaacgtgaag cgactgctgc tgcaaaactg ctgcgacctg agcaacaaca 4560  
tgaatggtct tcggtttccg tgtttcgtaa agtctggaaa cgcggaagtc agcgccctgc 4620  
accattatgt tccggatctg catcgagga tgctgctggc taccctgtgg aacacctaca 4680  
tctgtattaa cgaagcgtg gcattgacct tgagtattt ttctctgggt ccgcgcctac 4740  
cataccgcca gttgtttacc ctcaaacgt tccagtaacc gggcatgttc atcatcagta 4800  
accggtatcg tgagcatcct ctctcgtttc atcggtatca ttaccccat gaacagaaat 4860  
tcccccttac acggaggcat caagtgaaca aacaggaaaa aaccgccctt aacatggccc 4920  
gctttatcag aagccagaca ttaacgcttc tggagaaact caacgagctg gacgcggatg 4980  
aacagcgaga catctgtgaa tcgcttcacg accacgctga tgagctttac cgcagctgcc 5040  
tcgcgcgttt cgggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 5100  
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 5160  
ttggcgggtg tcggggcgca gccatgacct agtcacgtag cgatagcgga gtgtatactg 5220  
gcttaactat gcggcatcag agcagattgt actgagagt caccatatgc ggtgtgaaat 5280  
accgcacaga tgcgtaagga gaaaataacc catcaggcgc tcttccgctt cctcgctcac 5340  
tgactcgctg cgctcggctc ttccggctgc gcgagcggta tcagctcact caaaggcggg 5400  
aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 5460  
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 5520  
ccctgacgag catcacaaaa atcgacgctc aagtcaagg tggcgaaacc cgacaggact 5580  
ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgacct 5640  
gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag 5700  
ctcacgctgt aggtatctca gttcgggtga ggtcgttcgc tccaagctgg gctgtgtgca 5760  
cgaaccccc gttcagcccc accgctgcgc cttatccggt aactatcgct ttgagtccaa 5820

cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc	5880
gaggtatgta	ggcggtgcta	cagagttctt	gaagtgggtg	cctaactacg	gctacactag	5940
aaggacagta	tttgggtatct	gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	6000
tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggg	ggtttttttg	tttgcaagca	6060
gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	ctacgggggc	6120
tgacgctcag	tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	6180
gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aaatcaatct	aaagtatata	6240
tgagtaaaact	tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	6300
ctgtctattt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	6360
ggagggccta	ccatctggcc	ccagtgtgc	aatgataccg	cgagaccac	gctcaccggc	6420
tccagattta	tcagcaataa	accagccagc	cggaagggcc	gagcgagaa	gtggtcctgc	6480
aactttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	taagtagttc	6540
gccagttaat	agtttgcgca	acgttggtgc	cattgctgca	ggcatcgtgg	tgtcacgctc	6600
gtcgtttggg	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgate	6660
ccccatgttg	tgcaaaaaag	cggttagctc	cttcggtcct	ccgatcgttg	tcagaagtaa	6720
gttggccgca	gtgttatcac	tcatggttat	ggcagcactg	cataattctc	ttactgtcat	6780
gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	tctgagaata	6840
gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	ccgcgccaca	6900
tagcagaact	ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	aactctcaag	6960
gatcttaccg	ctggttgagat	ccagttcgat	gtaacccact	cgtgcacca	actgatcttc	7020
agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	7080
aaaaaagga	ataagggcga	cacggaaatg	ttgaatactc	atactcttcc	tttttcaata	7140
ttattgaagc	atztatcagg	gttattgtct	catgagcgga	tacatatttg	aatgtattta	7200
gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	ctgacgtcta	7260
agaaaccatt	attatcatga	cattaaccta	taaaaatagg	cgtatcacga	ggccctttcg	7320
tcttcaagaa						7330

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12P 13/04; C12N 9/02, 9/10, 9/88, 1/20, 15/00; C07H 21/04  
US CL : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/21772 A2 (OMNIGENE BIOPRODUCTS) 29 March 2001 (29.03.2001), see entire document.	1-10, 16-22, 29, 36-38, 42-49



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 August 2002 (22.08.2002)

Date of mailing of the international search report

13 NOV 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Tekchand Sainha

Telephone No. 703-308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 11-15, 23-28, 30-35, 39-41  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.